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ABSTRACT 
In order to prepare more effective inhibitors of 
ribonucleotide reductase a series of 4-substituted and 4,5-
disubstituted catechols were synthesized and tested. The 
derivatives synthesized were also examined for their 
antitumor activity against 11210 leukemia in mice. A free 
radical scavenging assay was performed to establish what 
electronic parameters may govern in vitro and/or in vivo 
activity. The molecular features of the most potent 
compounds were compared to the features of the natural 
substrate of reduction, CDP, UDP, GDP and ADP. 
The results obtained from the free radical assay did 
not show any correlation to the results observed either 
in vitro or in vivo. Enhanced activity, both in vitro and 
in vivo, was shown when the amide function of 3,4-
dihydroxybenzamide was substituted with a hydroxyethyl or a 
dimethylaminoethyl side chain. Reversal of the amide bond, 
ex. N-(3,4-dihydroxyphenyl)acetamide, resulted in a log 
unit increase as an inhibitor of ribonucleotide reductase. 
Antitumor activity was also substantially increased. The 
most potent compounds found in this study appear to 
physically resemble the molecular features found in the 
natural substrates. 
This research was supported by Grant J-36 of the 
Jeffress Trust, Richmond, Virginia. 
INTRODUCTION 
Cancer is a disease that is characterized by 
uncontrolled proliferation of cells and cellular components. 
Agents that can regulate the cellular events that lead to 
c�ll proliferation can be useful in cancer chemotherapy. 
Agents that are currently being used for therapeutic control 
of cancer can be divided into three categories: 1) 
alkylating agents 2) intercalating agents and 3) 
antimetabolites. Alkylating agents such as one- and two-
armed nitrogen mustards are relatively nonspecific. These 
agents are believed to covalently bind to the 7-position of 
guanosine. The modified DNA is unable to undergo normal 
replicative processes.
1 
Intercalators are large planar 
molecules capable of binding between base pairs of the DNA 
double helix strands and thereby modifying the natural 
stacking of the base pairs. This disrupts the ability of 
the DNA to act as a template for RNA synthesis. The 
inhibition of RNA leads to a depletion of essential proteins 
and ultimately to cell death.
2 
Antimetabolites are those 
agents that inhibit enzymes responsible for the production 
of essential cellular material such as DNA, RNA, proteins, 
and cofactors. Since DNA is required for cell division, 
inhibition of the synthesis of DNA precursors would provide 
an excellent strategic target in the control of 
proliferative diseases such as cancer. 
The components of DNA are deoxyribonucleotides derived 
from adenosine, guanosine, cytosine and thymidine. High 
amounts of the deoxyribonucleotides are required for the 
formation of DNA.3 However, the pool size of the 
deoxyribonucleotides is relatively small compared to the 
quantities needed during DNA synthesis.4•5 This means the 
deoxyribonucleotides must be generated upon demand. The 
enzyme responsible for the production of these essential 
components is ribonucleotide reductase, 2'-deoxyribo-
nucleoside-diphosphate: oxidized thioredoxin 2'-
oxidoreductase, EC 1.17.4.1. Reductase activity is 
intimately associated with tumor growth rates.6-9 Reduction 
of the ribonucleotides is the rate limiting step in the 
formation of DNA and is the first step solely committed to 
DNA h . 10 synt es1s. This enzyme would be an excellent target 
to inhibit DNA synthesis. 
Ribonucleotide reductase is responsible for the 
reduction of both purine and pyrimidine nucleotides. 
Ribonucleotide reductase can be isolated from both bacterial 
and mammalian tissue.10-12 Bacterial ribonucleotide 
reductase, being more readily available, has been more 
thoroughly examined than mammalian ribonucleotide reductase. 
Two sources exist for the bacterial enzyme, Escherichia coli 
and Lactobacillus leichmanni. Smith describes the physical 
2 
features of both mammalian and bacterial enzymes.13 
Mammalian ribonucleotide reductase is similar to the enzyme 
isolated from E. coli. Both enzymes are comprised of two 
subunits. The Bl and Ml, bacterial and mammalian 
respectively, subunits are responsible for the binding of 
the substrate to be reduced.12•14 Two regulatory sites are 
found in the Bl and Ml subunits.10•12•15 The high affinity 
regulatory site binds the positive effector that governs the 
nucleotide substrate to be reduced. Caras, et al. have 
shown that ATP acts as a positive effector for the reduction 
of CDP to dCDP.15 ADP and GDP do not act competitively for 
reduction when ATP is the only positive effector present in 
the assay. The low affinity site regulates the activity of 
the enzyme. Negative effectors of CDP reduction, dGTP, dATP 
and dTTP, act to inhibit the binding of CDP rather than 
inhibiting the reduction of bound substrate. Binding of the 
negative effectors to the low affinity site results in 
inhibition of the enzyme. The Bl and M1 subunits also 
. 12 16 conta1n several sulfhydryl groups. ' These are presumed 
to be the reducing equivalents in the enzyme. The B2 and M2 
subunits also share some common features. Through the use 
of ESR, electron spin resonance, a stable free radical has 
been detected in this enzyme. The free radical is located 
in the active site of the enzyme, specifically on a tyrosine 
residue.17-19 The B2 and M2 subunits also contain two atoms 
3 
of non-heme iron.19-22 The iron found in the active site 
has been determined to be in the +3 state. The tyrosinyl 
free radical is believed to be stabilized by the presence of 
the iron. Removal of the iron results in a loss of the ESR 
free radical signal. This loss of iron also inactivates the 
enzyme. Addition of iron in the +2 state results in the 
reactivation of the enzyme and regeneration of the ESR free 
radical signal. If the tyrosinyl free radical were 
discharged by a free radical scavenger, such as hydroxyurea, 
!• the enzyme is again inactivated. Regeneration of the 
free radical involves removal of the iron present and the 
insertion of iron in the +2 state. This would suggest that 
the free radical is important for the overall activity of 
the enzyme. The involvement of the tyrosinyl free radical 
in the reduction process is unclear. Stubbe and coworkers 
have suggested a possible mechanism of action for the enzyme 
that involves the free radical (Figure 1). It is proposed 
that the tyrosinyl free radical abstracts the 3'-J3 hydrogen 
of the ribose ring.23 A primary isotope effect can be 
observed when the ribose ring is specifically labeled with 
tritium at the 3'-)3 position. The hydrogen on tyrosine is 
presumed to be donated back to the 3'-}5 position at the end 
of the enzymatic process.24•25 This was examined by 
replacing the 3'-� hydrogen with a deuterium and examining 
the Nuclear Magnetic Resonance spectra. The deuterium was 
4 
found to be present at the 3'-)3 position in the reduced form 
of the ribonucelotide. Since the tyrosinyl free radical is 
also present in the oxidized form of the enzyme it is 
presumed that the hydrogen is transferred back to the 3'-;3 
position of the ribose ring from the tyrosine.26 According 
to the free radical mechanism proposed by Stubbe the 2'-C( 
hydroxy group is protonated to the oxonium ion. A 
sulfhydryl group is believed to be responsible for the 
donation of a proton to the hydroxyl group. The loss of 
water results in the formation of a carbocation at the 2' 
position. Generation of the free radical at the 3' position 
may help facilitate the loss of water and stabilize the 
resulting carbocation. The oxidation of the thiolate anion 
and a sulfhydryl group would result in the formation of a 
disulfide and a hydride. The hydride would then be 
introduced at the 2'-� position of the ribose ring. As 
stated before the radical at the 3' position abstracts the 
hydrogen from the tyrosine group providing the reduced 
product and the oxidized enzyme. Stubbe also has proposed 
an alternate mechanism (Figure 2).27 This proposal, 
however, does not account for any interaction of the free 
radical. The mechanism involves heterolytic cleavage of the 
3' C-H bond of the ribose ring. The 2'-� hydroxy group is 
eliminated to form the enol which can tautomerize to the 
ketone. Oxidation of the thiol groups to the disulfide is 
5 
Figure 1. A proposed Mechanism of Ribonucleotide Reductase 
Involving a Free Radical. 
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concomitant with the reduction of the ketone and the process 
is followed by the return of a proton to the 3'-;3 position. 
Both mechanistic schemes have been presented as if the 
reaction were to proceed stepwise. This is used for 
clarification and illustrative purposes only. The mechanism 
involved may occur via a concerted interaction and therefore 
proposed intermediates may not be isolatable. 
Ribonucleotide reductases from E. coli and mammalian 
sources are not completely identical with respect to their 
physical properties. The enzyme isolated from mammalian 
sources has been shown to be more sensitive to inhibitors 
than the bacterial enzyme. This is thought to be a result 
of the differences in the accessibility of the active sites 
of the isolated bacterial and mammalian enzyme. Mammalian 
enzyme can be inhibited by molecules that are much larger 
than hydroxyurea whereas the bacterial enzyme can only be 
reduced by molecules similar in size to hydroxyurea.14 3,4-
Dihydroxybenzohydroxamic acid, Didox, �' is a potent 
inhibitor of mammalian enzyme but it has little effect on 
the bacterial enzyme (Table 1).28 Larsen and coworkers have 
also shown a difference in the accessibility of the 
enzymes.14 Several hydroxamic acid derivatives were 
evaluated as inhibitors of the B2 subunit for ribonucleotide 
reductase. The inhibition results are shown in Table 2. 
From the data Larsen and coworkers suggested that the 
7 
Figure 2. Alternative Mechanism of Ribonucleotide Reductase 
Involving Heterolytic Cleavage of the 3'-j3-Hydrogen. 
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Table 1: Inhibition of Ribonucleotide Reductase from 
Bacterial and Mammalian Sources by Hydroxyurea and Didox. 
E. coli 
Calf Thymus 
------------------��2Q��2 ________________ _ 
3,4-dihydroxybenzo­
hydroxamic acid (Didox) 
2500 
30 
Hydroxyurea 
300 
270 
tyrosinyl free radical is situated in a pocket with a width 
of 4 A and a depth of 6 A for enzyme isolated from E. coli. 
� 
Inhibitors having the smallest width, 3.5 - 4�0 A, such as 
small aliphatic hydroxamic acids, are the most potent in the 
0 
series. Those compounds with a width greater than 5 A, such 
as the pivalo- and cyclohexanohydroxamic acids, were devoid 
of activity. The data given by Larsen is not presented as 
ID50 values, the dose that inhibits the enzyme by 50%. 
Rather, she has tested each compound at the same molar 
concentration and compared the percent activity of the 
enzyme. The enzyme isolated from mammalian source showed 
similar activity to the small hydroxamic acid derivatives 
compared to the enzyme from E. coli. However, the mammalian 
enzyme was approximately 75 times more sensitive to larger 
hydroxamic derivatives such as 3,4-dihydroxybenzohydroxamic 
acid. Larsen suggests that this difference can be accounted 
9 
Table 2: Reactivity of a Series of Hydroxamic Acids Towards 
the B2 Subunit of Ribonucleotide Reductase. 
Cmpd. 
No. 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Aceto 
n-Hexano 
n-Valero 
Propi.ono 
Phenylaceto 
lsohexano 
lsovalero 
lsobut.yro 
Pivalo 
Cyclohexano 
R-NHOH 
Relative Enzyme 
Activity (%) 
18 
36 
52 
57 
82 
90 
90 
108 
102 
Relative EPR 
Amplitudea 
21 
39 
45 
49 
42 
77 
a. Represents the observed amplitude of the tyrosinyl 
radical of the B2 subunit. 
10 
for by a greater accessibility to the free radical in the 
mammalian system. 
Non-hydroxamic acid derivatives have also been shown to 
have significant inhibitory activity against the mammalian 
enzyme. Polyhydroxybenzene derivatives have shown 
inhibitory activity against mammalian ribonucleotide 
reductase. 3,4-Dihydroxybenzohydroxamic acid, �. is a 
potent inhibitor of this enzyme. Compound � contains a 
hydroxamic acid and a polyhydroxybenzene function and it is 
unclear which moiety is responsible for the activity 
observed. Van't Riet and coworkers suggest that the 
Figure 3. Polyhydroxybenzene Derivatives That Show Enzyme 
Inhibition. 
R= CONHOH, COOCH3, CONH2, CONHNH2, 
CN, C(=NH)NH2, C(=NOH)NH2 
X= 1, 2, 3 
11 
majority of the activity observed is due to the 
polyhydroxybenzene moiety.29 Comparisons of hydroxyurea and 
some of its analogs show this relationship (Table 3). Both 
the 3,4,5-trihydroxybenzamide and 3,4,5-trihydroxybenzo-
hydroxamic acid showed the same inhibitory potency against 
ribonucleotide reductase relative to hydroxyurea. 
Inhibitors of Ribonucleotide Reductase: 
Hydroxyurea is a clinically useful agent for the 
treatment of leukemia.30 It is believed to inhibit the 
synthesis of DNA by inhibiting ribonucleotide reductase. 
Inhibition of this enzyme has been examined by several 
investigators utilizing various classes of inhibitors. 
Other classes of compounds that are not in clinical use 
include � -(N)-heterocyclic carboxaldehyde thiosemi-
carbazones, guanazole, hydroxamic acids and polyhydroxy-
benzene derivatives. 
Van't Riet and coworkers have investigated both the 
hydroxamic acid and polyhydroxybenzene derivatives as 
potentially useful chemotherapeutic agents.29•31 These 
compounds were evaluated for their ability to inhibit 
ribonucleotide reductase as well as their effect against 
L1210 leukemia in mice. Initial work began with 
12 
Table 3: Relative Inhibition of Ribonucleotide Reductase 
by Hydroxyurea and Some Related Analogs. 
Cmpd 
���-------------����-------------------------���2-���: ____ _ 
1 
13 
14 
15 
2 
16 
17 
18 
19 
20 
Hydroxyurea 
Benzohydroxamic acid 
3,5-Dihydroxybenzohydroxamic 
. 
. 
2,4-Dihydroxybenzohydroxamic 
3,4-Dihydroxybenzohydroxamic 
3,4-Dihydroxybenzamide 
acid 
acid 
acid 
3,4,5-Trihydroxybenzohydroxamic acid 
3,4,5-Trihydroxybenzamide 
2,3,4-Trihydroxybenzohydroxamic acid 
2,3,4-Trihydroxybenzamide 
a. The dose that inhibits the enzyme by 50%. 
13 
500 
400 
400 
250 
30 
so 
10 
10 
3.5 
5 
modifications of hydroxyurea. Table 4 is a compilation of 
some of the analogs synthesized and their results. The 
in vitro and in vivo results for these derivatives are not 
substantially different from that seen for hydroxyurea. 
These compounds were evaluated as inhibitors of mammalian 
ribonucleotide reductase that was isolated from calf thymus. 
According to the data shown by Larsen for the 3,4-
dihydroxybenzohydroxamic acid, all of the compounds listed 
in Table 4 should have adequate access to the active site of 
the enzyme. When the benzohydroxamic acid contained a 
hydroxyl or amino group on the aromatic ring, the activity 
observed, both in vitro and in vivo, increased 
substantially. These results can be seen in Table 5. 
Although the 2-hydroxy derivative has greater inhibitory 
activity, the 3-hydroxy analog gives a better effect in the 
in vivo assay. The addition of a second and third hydroxy 
group on the aromatic ring usually leads to compounds with 
higher activity as seen in Table 6. The enhancement of 
activity can only be seen for those compounds where the 
phenolic groups are vicinal. Separation of the phenolic 
groups, as in the case of the 2,4- 3,5- 2,5- or 2,6-
dihydroxybenzohydroxamic acids, does not lead to an 
enhancement of activity. Van't Riet29•33 and coworkers have 
suggested that the activity observed for these compounds is 
a result of the interaction of the polyhydroxy function 
14 
Table 4. Ribonucleotide Reductase Inhibition and Antitumor 
Activity of Some Hydroxamic Acids. 
R-NHOH 
Cmpd. In vitro Doseb 
No. R= ID50 V{ M) ILS
a mg/kg 
--------------------------------------------------------------
1 Hydroxyurea 500 62 (+10)c 2000 
3 Aceto- 1000 55 C+9l 500 
7 Phenylaceto- 1000 28 C+3l 500 
13 Benzo- 400 44 C+16) 500 
21 Picolino- 500 d 15e 
22 Nicotine- 800 32 (+9) 500 
23 Furano- 1000 toxic 25 
24 4-Nitrobenzo- 500 d 400 
25 4-Methoxybenzo- 500 d 250 
26 Malono- f d 250 
27 3,4-Dimethylbenzo- 300 d 200 
28 3,4-Dimethoxybenzo- 300 d 500 
29 3,4-Dichlorobenzo- 300 
30 2,4-Dichlorobenzo- 450 
a. Percent increase in life span of 8 drug treated, L1210-
bearing mice compared to 8 control mice. 
b. Drug dose given i.p. for 8 days which gave the maximum 
life span of L1210-bearing mice. 
c. Average + S.E. 
d. Less than 25% increase in life span compared to 
controls. 
e. The maximum dose treated which did not depress the life 
span compared to controls. 
f. Less than 20% inhibition at 1000 M. 
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Table 5. Ribonucleotide Reductase Inhibition and Antitumor 
Activity of Some Monosubstituted Benzohydroxamic Acids. 
�C-NHOH 
R ll 
0 
Cmpd. In vitro Doseb 
���-------�=--------------��22���---���:------�����-----------
31 
32 
33 
34 
35 
36 
37 
38 
2-Hydroxy-
3-Hydroxy-
4-Hydroxy-
2-Amino-
3-Amino-
4-Amino-
4-Methylamino-
4-Dimethylamino-
150 
350 
300 
120 
350 
150 
330 
500 
47 (+7)c 
77 (+12) 
32 (+6) 
so ( + 11) 
10 (+18) 
62 (+18) 
d 
500 
500 
200 
500 
500 
500 
a. Percent increase in life span of 8 drug treated L1210-
bearing mice compared to 8 control mice. 
b. Drug dose given i.p. for 8 days which caused the 
maximum life span of L1210-bearing mice. 
c. Average + S.E. 
d. Inactive, less than 20% increase in life span. 
e. The maximum dose 'tested which did not depress the life 
span compared to controls . 
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Table 6. Ribonucleotide Reductase Inhibition and Antitumor 
Activity of Polysubstituted Benzohydroxamic Acids. 
Cmpd. 
No. R= 
;n\,_C-NHOH 
R� ll n 0 
In vitro 
ID 50 � M) 
Dose b 
ILSa mg/kg 
------------------------------------- ------------------------
39 2,3-Dihydroxy 8 36 (+11) c 200 
15 2,4-Dihydroxy 300 47 C+7l 500 
40 2,5-Dihydroxy 200 30 C+14l 600 
41 2,6-Dihydroxy 100 23 C+11 l 188 
2 3,4-Dihydroxy 30 103 C+15l 600 
14 3,5-Dihydroxy 400 52 C+22 l 1000 
42 3 .• 4-Diamino 40 40 C+5J 300 
43 2-Hydroxy-4-amino 200 15 C+5l 1000 
44 2-Hydroxy-3-methyl 150 d 500e 
19 2,3,4-Trihydroxy 3.5 30 (+7) 125 
17 3,4,5-Trihydroxy 10 53 C+19 l 400 
45 3,4,5-Trimethoxy 100 d 500e 
a. Percent increase in life span of 8 drug treated L1210-
bearing mice compared to 8 control mice. 
b. Drug dose given i .p. for. 8 days which caused the 
maximum life span of L1210-bearing mice. 
c. Average + S.E. 
d. Inactive, less than 20% increase in life span compared 
to controls. 
e. The maximum dose tested that did not depress the life 
span compared to controls. 
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rather than the hydroxamic acid moiety with the active site. 
In order to investigate this suggestion several non­
hydroxamic acid derivatives of the polyhydroxybenzene system 
were developed. The moieties added to the polyhydroxy-
benzene structure are poor scavengers for free radicals. 
Therefore, the activity seen should be attributed to the 
polyhydroxybenzene function only.2� Almost all the examples 
shown in Table 7 inhibited calf thymus ribonucleotide 
reductase with an ID50 of 100 "{ M or less. Elford, � �·, 
suggest that increasing the number of vicinal hydroxyl 
groups from two to three generally results in higher 
activity both in vitro and in vivo. This rule may not apply 
for 3,4-dihydroxybenzonitrile, �. and 3,4,5-
trihydroxybenzonitrile, 22· Both analogs have the same 
inhibitory activity against the enzyme and the same 
antitumor effect in vivo. The polyhydroxybenzoates showed 
enhanced inhibition of the enzyme compared to hydroxyurea. 
However, in almost all cases the ester analogs were devoid 
of in vivo activity. This may be a result of the compound's 
inability to reach the active site with the ester moiety 
intact. Methyl 3,4,5-trihydroxybenzoate does provide a 
increase in life span of the treated mice above 25%. Even 
the benzoic acid derivative provides some activity, albeit 
at a high dose, 39% ILS at 1500 mg/kg. When the hydroxamic 
acid derivatives are compared to the same benzamide 
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Table 7. Inhibition of Ribonucleotide Reductase 
by Polyhydroxybenzene derivatives. 
Cmpd. Dose c 
No. Rl R2 R3 R4 ID50 t.{Ml 
a ILS(%)b mg/kg 
-----------------------------------------------------------
-
1 Hydroxyurea 500 62 (+10) 
46 COOCH3 H H OH 100 d 47 COOCH3 H OH H 70 d 48 COOCH3 H OH OH 8 d 49 COOCH3 OH OH H 30 45 (+4) 
so C000 OH OH H 15 
51 CONH2 H OH H so 35 ( +11) 52 CONH2 H OH OH 5 48 c+n 53 CONH OH OH H 10 42 Ct"Sl 
54 CONH�H3 OH OH H 25 55 CONHNH2 OH OH H 15 Toxic 56 CN H OH H 8 16 
57 CN OH OH H 8 34 
58 COOH OH OH H 100 39 (+9) 
a. Dose that provide 50% inhibition of Ribonucleotide 
Reductase. 
2500 
500 
500 
800 
250 
1200 
200 
250 
500 
95 
118 
1500 
b. Percent increase in life span of 8 drug treated Ll210 
bearing mice compared to 8 control mice. 
c. Drug dose given i.p. for 8 days which caused the maximum 
increase in life span compared to controls. 
d. Inactive, less than 25% increase in l·ife span compared to 
controls. 
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derivatives the inhibitory activity is essentially identical 
(Table 3). The in vivo activity follows a similar pattern. 
Compounds 53 and 17 show similar results against 11210 tumor 
in mice, 42% ILS at 250 mg/kg and 53% ILS at 400 mg/kg 
respectively. The 3,4-dihydroxy analogs show a different 
relationship. The benzohydroxamic acid analog provides an 
ILS of 103% at 600 mg/kg whereas the benzamide analog only 
provides an ILS of 35% at 1200 mg/kg. Both compounds have an 
equal ability to inhibit the enzyme. The difference 
observed in vivo may be a result of poor biodistribution of 
the amide analog. Elford, et �·· has shown that the 
relative activity observed in vivo correlates with the 
ability of the polyhydroxybenzene analogs, non-hydroxamic 
acid, to scavenge free radicals.33 An exception to this 
correlation exists with the alkyl-polyhydroxybenzoates. 
Derivatives of this type show good in vitro activity as well 
as good free radical scavenging ability. They do not, 
however, show activity in vivo. This is probably due to the 
rapid metabolism of the ester to the carboxylic acid. As 
noted earlier one possible .mechanism for enzyme inhibition 
involves the discharge of the free radical located at the 
tyrosinyl residue in the active site. Early work 
investigating the mode of action of the polyhydroxybenzene 
analogs centered on the idea of iron chelation. Such 
chelation would disrupt the stability of the radical and 
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thereby inhibit the enzyme. Robertson and Van't Riet found 
little difference in the ferric-complexing abilities of 
various hydroxy-substituted benzohydroxamic acids, while 
these analogs can exhibit a wide range of enzyme 
inhibition.34 The correlation of free radical scavenging 
and the observed activity of the polyhydroxybenzene system 
would lend support to the proposed free radical mechanism.33 
The work performed by Van't Riet and coworkers provided a 
new class of compounds to be investigated as potential 
anticancer chemotherapeutic agents. 
Dopamine, 59, has been shown to possess activity 
against various form of experimental cancers.35 Driscoll 
synthesized a large number of dopamine analogs that were 
tested as antitumor agents. The compounds described by 
Driscoll were only tested in vivo. From the data obtained, 
he defined parameters governing the structure activity 
relationship for the series of compounds tested.35 As is 
the case with compounds described by Van't Riet, � �·, the 
benzene ring requires the presence of vicinal hydroxyl 
groups. Addition of a third hydroxyl group increased 
activity. Dopamine gave a 68% ILS at 600 mg/kg and 3,4,5-
trihydroxyphenethylamine, 60, gave an ILS of 68% at 
200 mg/kg. This pattern of activity was also shown to occur 
with the compounds described by Van't Riet.29,3l,33 
Methylation of the phenols to the methoxy analogs abolished 
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in vivo activity. The alkyl side chain was varied between 
one and two carbon units, however, no difference in activity 
was observed. Higher homologation beyond two carbons nor 
lower homologation to the aniline were examined. Activity 
observed for the addition of a small alkyl group to the 
terminal nitrogen did not substantially differ from the 
primary nitrogen. However, addition of groups larger than 
methyl resulted in lower effectiveness of the drug. 
Driscoll states that all catechol analogs containing a 
carbonyl are inactive. The statement is misleading in part. 
All the inactive compounds tested by Driscoll containing the 
carbonyl were carboxylic acids. Other compounds containing 
a carbonyl, such as 3,4-dihydroxybenzaldehyde; §1_, showed 
activity in his test model (31% ILS at 200 mg/kg). Van't 
Riet has also shown that carboxylic acid derivatives are 
essentially without activity.29 When the carboxylic acid 
was functionalized as an amide, significant activity could 
be observed. The structure activity relationship set forth 
does suggest that compounds most likely to be good 
candidates as clinically useful agents possess the vicinal 
hydroxybenzene moiety. 
Wick also investigated analogs of dopamine as potential 
antitumor agents. He proposed that the dopamine analogs 
inhibited DNA synthesis by inhibiting DNA polymerase.36•37 
Van't Riet, et al. suggested that the antitumor activity was 
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related to the inhibition of ribonucleotide reductase 
activity. To identify the site of inhibition during DNA 
synthesis, enzyme inhibition studies were performed on 
ribonucleotide reductase, thymidine kinase and DNA 
polymerase.33 At concentrations where 50% inhibition occurs 
for ribonucleotide reductase, approximately 30�M, none of 
the compounds tested were inhibitory to thymidine kinase or 
DNA polymerase. The later two enzymes were not 
significantly affected even at a dose of 1 mM. The 
structure activity relationship generated by Wick further 
supports the importance of the catechol moiety. Although 
data are limited, it appears that homologation of the alkyl 
side chain detracts from the activity. N-Acetyldopamine, 
63, inhibits the mammalian reductase by 50% at a dose of 
400
1
M while the antitumor properties have been reported to 
be similar to 3,4-dihydroxybenzylamine (53% ILS at 600 
mg/kg). It is unclear at present why N-acetyldopamine shows 
good in vivo activity with poor in vitro activity. The 
higher than expected activity may be a result of metabolism 
to a more active form or a difference in biodistribution. 
Wick, Driscoll and Van't Riet began their 
investigations utilizing compounds that were structurally 
unrelated. However, the structure activity relationships 
developed at present by each investigator are very similar. 
The polyhydroxybenzene system appears to be a key element in 
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the overall scheme. Some evidence suggests that the 
presence of a third hydroxyl group on the aromatic ring is 
unnecessary for maximal activity (ie. the benzonitrile 
analogs). Further work to establish additional structural 
requirements is needed to better understand the interaction 
of these compounds with ribonucleotide reductase and to 
develop useful chemotherapeutic agents of this class. 
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RESEARCH AIMS 
Further work is necessary to more accurately define the 
structural requirements for improved binding of the 
polyhydroxybenzene derivatives to mammalian ribonucleotide 
reductase. The analogs synthesized will be evaluated for 
their ability to inhibit the conversion of CDP to dCDP by 
mammalian reductase. Those analogs possessing significant 
inhibitory activity against the mammalian enzyme will also 
be evaluated as antitumor agents against L1210 leukemia in 
mice. The proposed mechanism for ribonucleotide reductase 
involves a free radical located in the active site of the 
enzyme. The polyhydroxybenzene compounds have been shown to 
scavenge for free radicals effectively.33 Elford and 
coworkers have demonstrated a correlation between the 
ability of polyhydroxybenzene compounds to scavenge for free 
radicals and their antitumor property. The compounds 
developed will be examined for their ability to discharge a 
free radical in a chemical assay. A Hammett analysis of the 
free radical assay data will be performed. These results 
will be compared to the activity found in both the enzyme 
and antitumor assays to determine if any correlation exists. 
Initial analogs synthesized will contain an amide 
functionality on the polyhydroxybenzene ring since the amide 
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group is relatively stable in vivo. Aralkyl substitutions 
on the amide nitrogen will be employed to determine if 
lipophilic binding occurs. Aralkyl substitutions can also 
show whether steric ·restraints to binding are present. 
Substitutions on the amide nitrogen with an alkyl chain 
containing a polar funtionality, such as hydroxyl, will be 
synthesized and examined. Both 3,4,5-trihydroxy- and 3,4-
dihydroxybenzamide analogs will be synthesized and examined 
in vitro and in vivo. Their results will be compared to 
determine whether the presence of the third hydroxyl group 
is required for maximal activity. Since N-acetyldopamine 
has been shown to possess activity in experimental tumor 
models, placement of the amide function further from the 
aromatic ring will be examined through homologation or 
conjugation to see if a spatial arrangement of the amide and 
the aromatic ring is required. Reversal of the amide to 
form polyhydroxyanilides will be examined to determine if 
the orientation of the amide bond itself is important. 
Functionalities other than carboxamides, ie. sulfonamide, 
ureido, nitrile, amidoxime, will be examined. Additional 
substitutions on the polyhydroxybenzene ring with groups 
such as methyl, bromo, methanesulfonyl, or cyano will be 
evaluated in the free radical assay. 
The structural features of various active compounds 
will be compared utilizing molecular modeling techniques. 
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Additionally, these compounds will be compared to the 
natural substrates of ribonucleotide reductase to determine 
if any structural similarities exist. 
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RESULTS AND DISCUSSION 
Chemical Synthesis: 
Synthesis of N-substituted 3,4,5-trihydroxybenzamides 
was accomplished according to the procedure outlined in 
Scheme I. The synthetic procedure is an extension of that 
used by Van't Riet and coworkers31. Gallic acid was 
esterified when heated in methanol containing a catalytic 
amount of sulfuric acid. Aminolysis of the ester,49, 
occurred at temperatures greater than 130°C at atmospheric 
pressure to give compounds 64(a-d). Not all amines will 
react with the ester to provide the desired amides. Amines 
with low boiling points, ammonia and butylamine, are too 
volatile and did not react under these conditions. 
Secondary amines, in general, would not react with 49 to 
provide the appropriate amides. If temperature were the 
only requirement for aminolysis to take place, then N­
benzylmethylamine, with a boiling point of 187° C, should 
have provided the appropriate amide. However, only the 
ester was recovered from the reaction medium. Steric 
hindrance, as well as the boiling point, may be related to 
the amine's inability to.react with the ester, 49. An 
alternate method of synthesizing the desired amides was 
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employed. The acyl chloride group is a more reactive 
functionality than the ester. The acid chloride of gallic 
acid was prepared by treatment with thionyl chloride. The 
intermediate acid chloride was not isolated. Treatment of 
the acid chloride with the appropriate amine, dimethylamine, 
resulted in the formation of amide, 65 (Scheme II). Similar 
procedures were evaluated for the synthesis of N-substituted 
protocatechuic amides. Aminolysis of methyl 3,4-
dihydroxybenzoate, 66, resulted in N-(2-hydroxyethyl)-3,4-
dihydroxybenzamide, 67a (Scheme Ill). The acyl chloride 
intermediate was utilized to provide a more reactive 
functionality. The acid chloride synthesized was not 
isolated nor characterized. Reacting ammoni� with the acid 
chloride resulted in the unsubstituted amide, compound 51, 
Attempts to react the acyl chloride with benzylamine and 
phenethylamine failed to produce the appropriate products. 
Protection of the phenols was desired to prevent their 
involvement with the acid chloride function. In Scheme IV 
the phenolic groups are converted to acetoxy groups by 
treating 3,4-dihydroxybenzoic acid, 66, with acetic 
anhydride. Decomposition of the mixed anhydride in boiling 
water gave 3,4-diacetoxybenzoic acid, compound 68. 
Treatment of 68 with thionyl chloride reaulted in the 
formation of the the acid chloride, 69, which was stable 
under a nitrogen atmosphere in the refrigerator for several 
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months. The acid chloride was dissolved in ethyl acetate 
and two equivalents of an amine, such as benzylamine, were 
added. The byproduct of the reaction, the amine 
hydrochloride, was removed by filtration. The filtrate was 
concentrated under reduced pressure to give the 3,4-
diacetoxybenzamide derivatives, 70(b-f). In most cases 
these amide intermediates were not isolated but were 
subjected to the conditions of deprotection. Deprotection 
was carried out under basic conditions. Treatment with 
sodium hydroxide or sodium carbonate hydrolyzed the acetyl 
ester groups. The desired products, 67(b-f), precipitated 
from the solution upon addition of hydrochloric acid ( pH 
between 2 and 4). Generally the use of sodium hydroxide or 
sodium carbonate as a deprotective agent resulted in low 
yields, and purification of the product was tedious. The 
amide intermediates were relatively insoluble in aqueous 
media and ,therefore, required heating in order to increase 
solubility. Such heating with sodium hydroxide or carbonate 
may result additionally in hydrolysis of the amide group. 
Recent literature reported the use of pyrrolidine as a 
selective agent for the deprotection of phenolic esters 
versus aliphatic esters.38 Deprotection with pyrrolidine 
occurs at room temperature in 5 to 15 min. Pyrrolidine's 
reactivity may be partially attributed to the reduced steric 
hindrance of the amine. When pyrrolidine was used as a 
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deprotective agent, the yields observed were generally 
higher, and the products were less tedious to purify. When 
reaction temperatures are elevated, pyrrolidine was shown to 
react with aliphatic esters. Compound � . 1-(2-(3,4-
dihydroxybenzamido)-acetyl)-pyrrolidine, shown in Scheme 
IVa, was synthesized under these ·conditions. N,N-Dibenzyl-
3,4-diacetoxybenzamide was synthesized from the acid 
chloride, 69, and N,N-dibenzylamine. Deprotection was 
accomplished utilizing pyrrolidine at an elevated 
temperature (Scheme IVb). The amide group, as anticipated, 
does not react with pyrrolidine even at elevated 
temperatures. 
3,4-Dihydroxyhippuric acid, 74a, a desired analog was· 
prepared via two different synthetic schemes. Smith13, 
utilizing the procedure of Ito and Neilands39, synthesized 
the hippuric acid from the condensation of 3,4-
dihydroxybenzoic acid and ethyl glycinate with 
dicyclohexylcarbodiimide, followed by hydrolysis of the 
ethyl hippurate to 74a. The reported yield by Smith was 40 
mg (0.7% theoretical yield}. Larger quantities of the 
hippuric acid and the corresponding ethyl ester were desired 
for testing. The method described by Kametaka40 involves 
protecting the phenolic groups with ethyl chloroformate. 
The protected protocatechuic acid is converted to the acid 
chloride with thionyl chloride. Treatment of the acid 
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chloride with ethyl glycinate followed by exhaustive 
hydrolysis of all ester bonds yielded the hippuric acid. 
This procedure results in the formation of the hippuric acid 
product in fairly good yield. Ethyl ·3,4-dihydroxyhippurate 
cannot be isolated from the procedure of Kametaka. The use 
of an ester as a protective group would be unsatisfactory 
for the synthesis of this desired analog. The use of a more 
stable protective group was desired. 
Protection of the phenolic groups as ethers was 
examined. The methyl ether, a chemically stable protective 
group, requires the use of a Lewis acid, such as BBr3 or 
AlCl3, for deprotection. Several amides, initially made by 
aminolysis, were synthesized with the methyl ether 
protective group present. Deprotection with BBr3 or AlCl3 
was not successful and the isolation of desired amides could 
not be obtained utilizing these procedures. It is assumed 
that the Lewis acid does remove one or both methyl groups to 
form a metal complex with the phenolic groups since the 
starting material could not be isolated. Conditions used to 
decompose the metal complex may have also caused further 
decomposition of the desired product. In many cases only 
black tar residues were formed. Milder means of removing 
the protective group were desired. The benzyl group of the 
ether, which can be removed by hydrogenolysis, was used as 
the protecting group to synthesize the hippuric acid and the 
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corresponding ethyl ester, 74a and 74b (Scheme V). 3,4-
Dibenzyloxybenzoic acid, 72, was synthesized according to 
the method of Priestley and Moness.41 The acid chloride was 
generated with thionyl chloride, followed by treatment with 
benzyl glycinate to give benzyl N-(3,4-dibenzyloxybenzoyl)-
glycinate, 73a. Deprotection via hydrogenolysis yielded the 
hippuric acid analog, 74a, with an overall yield of 45%. 
Treatment of the acid chloride with ethyl glycinate, 
followed by hydrogenolysis, gave 74b in 45% overall yield. 
The benzyl ether protective group was utilized for the 
synthesis of N-acyl derivatives of 3,4-dihydroxyaniline and 
other reverse amides (Schemes VI, VIa-c). The phenolic 
groups of catechol, 4-methyl catechol and 3,4-
dihydroxybenzonitrile, 75a, 75b and 75c respectively, were 
benzylated according to the method of Druey42. Nitration of 
the 1,2-dibenzyloxybenzene, 76a, was accomplished utilizing 
synthetic procedures of Page and Clinton43. Nitration of 
76a occurs at the 4-position selectively. The large bulk of 
the benzyloxy groups may prevent electrophilic substitution 
from occurring at the 3-position. Keffler44 has shown that 
the nitration of 3,4-dimethoxybenzonitrile occurs at its 6-
position. Keffler states that the equivalent 5-position of 
a 4-substituted catechol is the most reactive site. 
Utilizing methods analogous to that of Keffler, 4-
substituted-1,2-dibenzyloxybenzene analogs were nitrated at 
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the 5-position. The substituent at the 4-position included 
methyl or cyano, compounds 76b and 76c respectively. That 
substitution at the 5-position occurred was supported by the 
Nuclear Magnetic Resonance (NMR) data. If the nitration had 
occurred at the 3-position of a 4-substituted-1,2-
dibenzyloxybenzene, coupling of the hydrogens at the 
respective 5 and 6 positions should be detected. The 
coupling constant for ortho hydrogens is approximately 8 
Hz.45 In this example two doublets should be present. 
Nitration at the 6 position of the 4-substituted-1,2-
dibenzyloxybenzene would leave two hydrogens on the catechol 
ring meta to each other. The coupling constant for meta 
hydrogens is 2 - 4 Hz. This would also show two doublets, 
but with a smaller splitting pattern. Nitration at the 5-
position, the desired position, of 4-substituted-1,2-
dibenzyloxybenzene would leave the two remaining hydrogens 
of the catechol ring para to each other. The coupling 
constant for hydrogens para to each other is essentially 
zero. In this case only two singlets should be observed. 
The nitration products of both the 4-methyl and 4-cyano 
intermediates show two singlets of equal intensity 
indicating nitration at the desired position. Reduction of 
the nitro group was accomplished according to the method of 
Balaban46 using sodium dithionite. Compound 77b, 2-methyl-
4,5-dibenzyloxynitrobenzene, could not be reduced to the 
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aniline using sodium dithionite. The use of a selective 
catalyst, Raney nickel, under a hydrogen atmosphere resulted 
in the formation of the aniline, 7Sb, without loss of the 
benzyl protective groups. Acylation of the resulting 
anilines was accomplished by treatment with acetyl chloride, 
benzoyl chloride or sodium cyanate. Treatment of 3,4-
dibenzyloxyaniline with methanesulfonyl chloride at room 
temperature resulted in ring sulfonylation to give compound 
�. N-(2-methanesulfonyl-4,5-dibenzyloxyphenyl) 
methanesulfonamide. When the temperature of the reaction 
was reduced to 0°, ring sulfonylation did not occur. The 
desired intermediate compound, SOc, was produced. 
Hydrogenolysis using 10% palladium in methanol resulted in 
the formation of the desired products, although limited 
solubility of the starting material was observed. Compound 
SOd, N-(3,4-dihydroxyphenyl)acetamide, was synthesized by 
acylating 3,4-dibenzyloxyaniline with acetic anhydride, 
followed by debenzylation under the conditions described. 
The overall synthetic yield was approximately 40% for 5 
synthetic steps. An alternate synthetic method for SOd 
involves two steps with an overall yield of 65% (Scheme 
VII). Commercially available 4-nitrocatechol, � . was 
reduced using 10% palladium in methanolic HCl. The 3,4-
dihydroxyaniline hydrochloride,SS, was then selectively 
acylated at the amine utilizing acetic anhydride/sodium 
47 
Scheme VII 
HO�NO, 
HO E 
H2/Pd/C 
. MeOH/HCI 
HO--IQ\- NHCOCH 3 
_ "P BOd 
HO 
48 
acetate in water. 
Bromination of N-(3,4-dihydroxyphenyl)acetamide, 80d; 
N-(3,4-dihydroxyphenyl)benzamide, 80a; and N-(3,4-
dihydroxyphenyl)methanesulfonamide, 80b was accomplished by 
treating the various amides with Br2 in glacial acetic acid 
(Scheme VIII). The position of bromination was determined 
to be at the 6-position via NMR analysis. Spectral data 
showed two singlets for the para hydrogens of the 
methanesulfonamide and benzamide derivatives. The acetamide 
analog gave only one singlet which integrated for 2 
hydrogens. 
Homologation and conjugation of the amide function was 
·accomplished according to Scheme IX. The appropriate acid 
was treated with thionyl chloride to form the acyl chloride, 
which was then treated with ammonium hydroxide to yield the 
desired amides, 91(a,b). 2-(3,4-
Dihydroxyphenyl)acetamidoxime hydrochloride,93, is the 
higher homolog of the active compound 3,4-
dihydroxybenzamidoxime, 94. Synthesis of 93 is carried out 
by treating 2-(3,4-dihydroxyphenyl)acetonitrile, 92, with 
hydroxylamine (Scheme X). 
Protection of the phenolic groups appears to be 
essential for the synthesis of a large number of analogs 
with varying substitution patterns. Synthesis without a 
protective group limited the number of analogs that could be 
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Scheme VIII 
HO� R 80 c-d 
HO 
Br 
HO-\Q)-R 
HO 
89 a- c 
R= -NHCOC6H5 a 
-NHCOCH3 
. 50 
Scheme IX 
[ HO� X-COCI l HO 
1. NH40H 
2. HCI/H20 
HO�X� ��NH, 
HO 
-CH=CH- b 
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Scheme X 
20 HO�CH,CN 
HO 
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obtained. The use of the acetoxy protective group was quite 
useful in several synthetic schemes, however, the use of 
this mode of protection could not be utilized in all 
situations. An ether protective group is substantially more 
stable than the ester group and the ether function can 
tolerate a wide range of reaction conditions. However, 
initial results utilizing ether protection, methoxy groups, 
was discouraging. Attempts to deprotect also resulted in 
product decomposition. Protection with the benzyloxy group 
proved useful due to it's ability to be removed under milder 
conditions, hydrogenolysis. The only constraint for 
utilizing the benzyloxy protective group lies with the 
susceptibility of additional functionalities to reduction by 
-H2. For those instances the use of ester protection may be 
more advantageous. 
The compounds synthesized were characterized by IR and 
1H NMR. Those compounds previously unreported were also 
evaluated by elemental analysis and gave satisfactory 
results (within 0.4%). 
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Biological Results: 
Studies to examine the inhibitory properties of the 
synthesized material against ribonucleotide reductase, 
isolated from Novikoff hepatoma or HeLa cells, were 
performed by Howard L. Elford according to the procedure set 
forth by Elford, � a1.47 The assay measures the ability of 
a compound to inhibit the conversion of CDP to dCDP by 
ribonucleotide reductase. Compounds to be tested were 
dissolved in water or in a mixture of water and 1% ethanol 
or 2% DMSO. The mixed solvents are not inhibitory at these 
concentrations33. Activity for the inhibitors is reported 
as rn50, the dose that provides 50% inhibition of the 
enzyme. The enzyme inhibition results for substituted 
pyrogallol derivatives are shown in Table 8. Addition of a 
methyl on the amide nitrogen, compound 54, does not appear 
to greatly affect the inhibitory property observed. The 
addition of the bulky benzyl group, as seen in compound 64a, 
provides the same inhibition. Other groups such as the 2-
hydroxyethyl analog, 64c, show a slight decrease in 
inhibitory activity. Further homologation to the 3-
hydroxypropyl derivative, 64d, results in complete loss of 
activity. This loss of activity is not understood at this 
time. The preferred conformation may be such that 
interaction with the active site of the reductase is not 
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Table 8. Inhibition of Ribonucleotide Reductase by 5-
Substituted Pyrogallols.a 
Cmpd. b No. R= ID50 V{Ml 
----------------------------------------------------- -------
53 (c) CONH2 10 
54 (c) CONHCH3 25 
64a CONHCH20 25 
64c CONH(CH2J20H 40 
64d CONH(CH2J30H >500 
65 CON(CH3J2 >500 
(c) Hydroxyurea 500 
a. Enzyme inhibition studies were performed by Dr. Elford. 
b. Dose of test compound that inhibits the enzyme by 50%. 
c. Material supplied by Dr. Van't Riet. 
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favored. A loss of activity is also observed for the 
disubstituted amide, 65. This is the only disubstituted 
amide tested as an inhibitor of ribonucleotide reductase for 
the 3,4,5-trihydroxybenzamide series. 
The seven trihydroxybenzamide derivatives tested as 
reductase inhibitors were evaluated for their antitumor 
activity against L1210 leukemia in mice. The data from the 
assays were supplied by Galen Wampler of the Medical College 
of Virginia. Antineoplastic activity was assessed using 
20 g L1210 leukemia-bearing female B6D2F1 mice. Diluted 
ascitic fluid, 0.1 mL (105 cells), was administered i.p. to 
the mice. The life span of the untreated mice varied from 7 
to 9 days. Test agents were administered i.p. once daily 
for 8 days starting on day 1. Compounds were tested at 
three different doses in the range of 100 to 1000 mg/kg. 
Other dose levels were given dependent on toxicity. 
Activity is reported as the percentage increase in life 
span, % ILS, of the treated mice compared to the control 
mice. Compounds showing activity were retested to determine 
the optimum dose required for maximal response. According 
to the protocol set forth by the National Institutes of 
Health, activity is defined as the ability of a test 
compound to increase the life span of the test mice greater 
than 25% of the control mice. Results for the N-substituted 
gallamides are shown in Table 9. The addition of a methyl 
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Table 9. Anlineoplastic Activity of 5-Substituted 
Pyrogallols. 
Cmpd. 
No. R= 
53 (f) 
54 (f) 
64a 
64b 
64c 
64d 
65 
CONH2 
CONHCH3 
CONHCH20 
CONH ( CH2) 20 
CONH(CH2)20H 
CONH(CH2)30H 
CON(CH3J2 
Doseb 
mg/kg 
250 
500 
200 
200 
381 
600 
870 
42 
60 
e 
e 
72 
e 
30 
a. Antitumor assay performed by Dr. Wampler. 
� 
5d 
� 
29 
� 
8 
+ 
7 
b. Drug dose given i.p. for 8 days which caused maximum 
increase in life span of L1210 bearing mice. 
c. Percent increase in life span of 8 drug treated, L1210 
bearing mice compared to 8 control mice. 
d. Average + S.E. 
e. Inactive� less than 25% increase in life span compared to 
controls·. 
f. Material supplied by Dr. Van't Riet. 
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group, 54, appears to cause little change in antineoplastic 
effectiveness compared to gallamide, 53. The addition of 
bulkier substituents, such as benzyl, 64b, and phenethyl, 
64c, result in loss of activity. The addition of the 
aralkyl side chain does not greatly affect in vitro activity 
but does significantly reduce in vivo activity. This may be 
a result of poor biodistribution. The 2-hydroxyethyl 
derivative, 64c, shqws slightly enhanced antitumor activity 
compared to gallamide. The hydroxypropyl derivative, 64d, 
is inactive in the in vivo assay. This compound was also 
inactive in the in vitro assay. The N,N-disubstituted 
analog, 65, does show some activity in vivo but only at a 
relatively high dose, 30% ILS at 870 mg/kg. El'r'ord, ei? 
�.,33 suggest that those compounds with good in vitro 
activity usually have good in vivo activity, and those with 
poor enzyme activity will have poor antitumor activity. 
Substituted catechol derivatives were evaluated for 
their inhibition of reductase activity (Table 10). The 
activity of 3,4-dihydroxybenzamide, 2!• and the N-methyl 
derivative, 95, are identical. In an attempt to examine the 
bulk effect for substitution on the amide nitrogen, three 
aralkyl derivatives were synthesized; the N-benzyl, 67b; the 
N-phenethyl, 67c; and the N-phenylpropyl, 67d, derivatives. 
Only the activity for the N-benzyl derivative, 67b, could be 
examined due to the insolubility of compounds 67c and 67d 
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Table 10. Inhibition of Ribonucleotide Reductase by 4-
Substituted Catechols.a 
H01}R 
HO 
Cmpd. b 
���-----------�=----------------------��2Q_���-------------
75a (d) H 60 
51 (d) CONH2 50 
95 (d) CONHCH3 so 
67b CONHCH20 70 
67c CONH(CH2)20 c 
67d CONH(CH2)30 c 
67f CONH(CH2)2N(CH3)2 .HCl 
20 
96a (d) COCH2NH(CH2l20H . HCl 10 
96b (d) COCH2NH(CH2l30H .HCl 10 
97 (d) COCH2NH(CH2CH20Hl2 .HCl 8 
SOd NHCOCH3 5 
a. Enzyme inhibition studies were performed by Dr. Elford. 
b. Dose of test compound that inhibits the enzyme by 50%. 
c. Test compounds could not be evaluated due to their 
insolubility in water or a mixture of water and 1% 
ethanol or 2% DMSO. 
d. Material supplied by Dr. Van't Riet or obtained from 
commercial source. 
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in water or a mixture of water and ethanol or DMSO. The 
inhibitory activity observed for 67b was similar to the 
unsubstituted amide, 2!_, 70A.(M and 50-t(
M respectively. 
Although the activity observed for the 3,4-
dihydroxybenzamides is less than that of the corresponding 
3,4,5-trihydroxybenzamides, the activity for the alkyl and 
aralkyl substitutions appears to follow a similar pattern. 
The N-(2-hydroxyethyl)benzamide, 67a, has not been tested as 
an inhibitor of ribonucleotide reductase, and therefore 
comparison with the corresponding trihydroxybenzamide analog 
is not available. The N-(2-dimethylaminoethyl)benzamide 
hydrochloride, 67f, similar in structure to 67a, has been 
tested and shows slightly improved activity as an inhibitor 
of ribonucleotide reductase ( 1D50 = 20-<(Ml. Other 4-
substituted catechols containing hydrophilic groups have 
shown improved activity. These include N-substituted 2-
amino-3' ,4'-dihydroxyacetophenone analogs, 96a and 96b. 
Unlike the case with substituted gallamides 64c and 64d, the 
hydroxyethyl, 96a, and the hydroxypropyl derivative, 96b, 
show equal inhibitory activity (lDso= lO�M). Even compound 
97, the bis(hydroxyethyl) analog, has comparable activity, 
8A(M· The inhibitory activity observed for the 
dihydroxyacetophenone derivatives is identical to the 
activity observed for 3,4,5-trihydroxybenzamide, 53. The 
presence of a third phenolic group is not essential for 
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activity if the benzene ring is appropriately substituted. 
Compound SOd, N-(3,4-dihydroxyphenyl)-acetamide, contains an 
amide bond that is reversed from that found in N-methyl-3,4-
dihydroxybenzamide, 22· The reversal of this amide bond 
leads to a 10 fold increase in inhibitory activity (ID50= 
5..t(M). Since the methyl group in 95 does not appear to 
contribute to the observed activity, the methyl group would 
not be expected to contribute greatly to the activity 
observed for SOd in the enzyme assay. Such an enhancement 
in activity can be attributed to improved binding to the 
active site of the enzyme or how the nitrogen, substituted 
directly on the ring, alters the catechol moiety's ability 
to interact with the enzyme. 
Several of the 4-substituted catechols have been 
examined for their antineoplastic activity (Table 11). 3,4-
Dihydroxybenzamide, 2!• exhibits antitumor activity at a 
relatively high dose, 35% ILS at 1200 mg/kg. The N-methyl 
analog, 95, provides the same ILS but at a substantially 
lower dose, 400 mg/kg. Since the activity observed for 
enzyme inhibition is similar for 2! and 95, it would appear 
the increase in antitumor activity of 95 may be due to 
better biodistribution. Placement of the benzyl, 67b; the 
phenylethyl, 67c; and phenylpropyl function, 67d, on the 
amide nitrogen may result in a loss of activity. Doses 
higher than 200 mg/kg could not be examined due to 
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Table 11. �ntineoplastic Activity of 4-Substituted 
Catechols. 
H012>- R 
HO 
Dose b ·Cmpd. 
No. R= mg/kg ILSC 
------------------------------------------------------------
51 (f) CONH2 1200 35 .:!:. 11 
d 
95 (f) CONHCH3 400 32 .:!:. 6 
67b CONHCH20 200 e 
67c CONH(CH2l20 200 e 
67d CONH(CH2J30 200 e 
67a CONH(CH2l20H 762 55 .:!:. 5 
67f CONH(CH2)2N(CH3)2 229 .HCl 
49 .:!:. 7 
SOd NHCOCH3 215 66 .:!:. 5 
91a CH2CONH2 644 47 .:!:. 9 
91b CH=CHCONH2 500 40 .:!:. 10 
96a (f) COCH2NH(CH2l20H 566 55 .:!:. 5 .HCl 
96b (f) COCH2NH(CH2)30H 349 40 .:!:. 8 .HCl 
a. Antitumor assay was performed by Dr. Wampler. 
b. Drug dose given i.p. for 8 days which caused maximum 
increase in life span of Ll210-bearing mice. 
c. Percent increase in life span of 8 drug-treated, Ll210-
bearing mice compared to 8 control mice. 
d. Average + S.E. 
e. Inactive� less than 25% increase in life span compared to 
controls. 
f. Material supplied by Dr. Van't Riet. 
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insolubility of the test compounds. The 2-hydroxyethyl 
analog, 67a, provides a 55% ILS at 762 mg/kg. Replacement 
of the hydroxyl group in 67a with a dimethylamino group, 
found in compound 67f, gives a similar ILS, 49%, but at a 
dose substantially smaller, 229 mg/kg. This 
dihydroxybenzamide analog, 67f, has the same activity as 
3,4,5-trihydroxybenzamide, 53, in both the in vitro and 
in vivo assays. This increase in activity would suggest 
that N-substitution, if appropriate, may provide additional 
binding at the active site of ribonucleotide reductase. 
Compound 80d, N-(3,4-dihydroxyphenyl)acetamide, where the 
amide bond has been reversed, shows slightly higher activity 
still, 66% ILS at 215 mg/kg. This compound is among the 
most potent of the polyhydroxybenzene derivatives tested to 
date in both the in vitro and in vivo assays. When 
compounds 80d and 95 (N-methyl-3,4-dihydroxybenzamide) are 
compared, a significant difference can be observed. The 
higher homolog of 2!• 3,4-dihydroxybenzamide, in which a 
methylene is inserted between the ring and the carbonyl is 
compound 91a. The activity seen for 91a is better than that 
observed for 95. Compound 91b has a carbon-carbon double 
bond inserted between the ring and the carbonyl. The 
conjugated amide analog exhibits modest antitumor activity, 
40% ILS at 500 mg/kg. The activity of the acetophenone 
derivatives, 96a and 96b, are also shown in Table 11. Both 
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compounds exhibit good activity. The hydroxyethyl and 
hydroxypropyl analogs, 96a and 96b, have similar antitumor 
activity. 
Comparisons between the 3,4,5-trihydroxybenzamide and 
similarly substituted 3,4-dihydroxybenzamide analogs could 
not be adequately evaluated. In the in vitro assay the 
trihydroxy analogs usually exhibited a 2 to 5 fold greater 
inhibitory activity than that provide by the dihydroxy 
analogs. Comparisons based on the results obtained in vivo 
are limited to a few analogs. Due to solubility 
restrictions direct comparison of several analogs could not 
be ascertained. 
Several of the derivatives synthesized in this study 
await analysis in both the in vitro and in vivo assays. 
Work is presently in progress to evaluate these derivatives 
as reductase inhibitors and as antitumor agents and the 
results obtained from these assays will be presented as they 
become available. 
Free Radical Scavenging: 
The derivatives synthesized are believed to inhibit 
ribonucleotide reductase by discharging the tyrosinyl free 
radical. As noted earlier the destruction of the free 
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radical located in the active site of the enzyme causes 
complete inhibition. Elford and coworkers33 showed a 
correlation between free radical scavenging and the ability 
of the compounds to inhibit ribonucleotide reductase. The 
derivatives tested by Elford and coworkers were primarily 
mono-, di- and trihydroxybenzohydroxamic acids. Only the 
effect of adding an additional hydroxyl function was 
observed and correlated with activity. Elford, et al.,29 
has shown that the hydroxamic acid group is not required for 
activity. Inhibitory activity can be observed for other 
functional groups, ie. ester and amide, on the 
polyhydroxybenzene moiety. The presence of these groups may 
influence the ability of the vicinal hydroxyl group to 
efficiently scavenge for free radicals. A Hammett analysis 
of a series of 4-substituted catechols was undertaken to 
determine to what extent substitution on the aromatic ring 
has on the ability of the catechol moiety to scavenge for 
free radicals. The method of analysis employed is analogous 
to the method described by Venker and Herzmann48. The 
radical scavenging ability of the substituted catechols was 
determined by measuring the destruction of the stable free 
radical diphenylpicrylhydrazyl, in the presence of the test 
compound. The absorbance at 518 nm of a 95�M solution of 
diphenylpicrylhydrazyl free radical in acetone was 
monitored. Diphenylpicrylhydrazyl radical is stable in dry 
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acetone for a time period of at least a week in the 
refrigerator. All the analogs tested were assayed against 
the same preparation of diphenylpicrylhydrazyl radical 
solution. The test compound was added at a final 
concentration of 47.5 -<-(M and the change of absorbance at 
518 nm with respect to time was recorded. Each compound was 
tested a minimum of three times, and the standard errors are 
reported. The free radical scavenging ability is expressed 
as the initial change in rate of absorbance/min. Data 
obtained for the 4-substituted catechols are shown in Table 
12. The rates observed were plotted against the Hammett 
sigma values (shown in Table 13).49 The best correlation 
exists with sigma-meta r= 0.340). The plot vf this· 
relationship is shown in Figure 4. The N-substituted 
dihydroxybenzamide analogs appear to show the same ability 
to scavenge for the free radical (0.079 - 0.091). This 
suggests that substituents on the amide nitrogen do not 
alter the catechol's radical scavenging ability. Within 
this series of analogs are four reverse amides, the 
benzamido, 80b; sulfonamido, 80c; ureido, 80a; and 
acetamido, 80d. These analogs show significantly different 
abilities to scavenge the free radical. Upon inspection of 
these points in Figure 4, the data appears to be rather 
widely dispersed and forms a line with a slope opposite that 
found for the entire collection of data. These four data 
66 
Table 12. Free Radical Scavenging of 4-Substituted 
Catechols. 
Cmpd. 
No. 
80c 
75a (d) 
91a 
95 
80d 
80b 
67a 
67b 
67c 
67d 
71 
46 
75b (d) 
87 (d) 
BOa 
HO§?>-R 
HO 
R= 
NHS02cH3 H 
CH{ONH2 CO HCH 
NHCOCH� 
NHC00 
CONHCH2CH20H CONHCH 0 
CONH(C�2)20 CONH(CH�)30 CON(CH2 )2 COOCH3 CN 
NO 
NHCONH2 
Ratea,b 
0.010 
+ 
0.015 + 
0.024 + 
0.081 + 
0.090 + 
0.090 + 
0.090 + 
0.091 + 
0.083 + 
0.080 + 
0.079 + 
0.215 + 
0.223 + 
0.253 + 
0.337 + 
oc 
.005 
.001 
.005 
oc 
.002 
.004 
.019 
.008 
.006 
.005 
.010 
.007 
.001 
.005 
a. A minimum of three data points were taken for each test 
compound. 
b. The rate of radical discharge is expressed as the initial 
change in absorbance/min at 518 nm. 
c. The rate observed was identical for all data points 
collected. 
d. Material supplied by Dr. Van't Riet or obtained from 
commercial source. 
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Table 13. Harrunett Sigma Values For Various Substituents. 
SIGMA 
--
Substituent para meta resonance inductive 
-----------------------------------------------------------
-
H 0 0 0 0 
CH3 -0.17 -0.07 -0.11 -0.04 
CH2CONH2 0.07 a a 0.05 
CONHCH3 0.36 0.35 0.01 0.21 
CONHCH2CH20H 0.36 0.35 0.01 0.21 
CONHCH20 0.36 0.35 0.01 0.21 
CONHCH2CH20 0.36 0.35 0.01 0.21 
CONHCH2CH2CH20 0.36 0.35 0.01 0.21 
CON(CH20)2 0.36 0.35 0.01 0.21 
COOCH3 0.45 0.37 0.16 0.34 
CN 0.66 0.56 0.13 0.56 
N02 0.78 0. 71 0.15 0.65 
NHS02CH3 0.03 0.20 -0.20 0.28 
NHCOCH3 0 0.21 -0.23 0.28 
NHC00 -0.19 0.02 -0.22 0.31 
NHCONH2 -0.24 -0.03 -0.30 0.21 
Br 0.23 0.39 -0.19 0.44 
S02CH3 0. 72 0.60 0.12 0.59 
a. Values are not reported. 
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Figure 4. Scavenging Ability of 4-Substituted Catechols Against 
Diphenylpicrylhydrazyl Radical . 
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points appear to form a straight line when compared with 
sigma resonance values (Figure 5). The data consist of only 
four points, the statistical correlation of the data would 
be questionable. Despite this fact, the data suggests that 
a high correlation with sigma-resonance may exist. If data 
points for the 4-amido analogs are removed from Table 12, 
the remaining data shows a high correlation with sigma-meta 
(r= 0. 996) (Figure 6). The addition of an electron 
withdrawing group in the 4-position of catechol appears to 
enhance free radical scavenging. 
Compound 82 is a 4-amido analog that contains a 
methanesulfonyl group at the 2-position. It showed an 
increase in radical scavenging over 80c, N-(3,4-
dihydroxyphenyl)methanesulfonamide, by a factor of 12. The 
addition of the methanesulfonyl group appears to enhance 
scavenging abilities. Additional modifications of the 4-
amido analogs, sulfonamide-, acetamide- and benzamido­
catechol, were examined to determine if the addition of 
electron withdrawing groups to the 4-amido structure would 
increase radical scavenging and if a correlation with 
electronic parameters could be shown. The compounds 
synthesized and the data from the free radical scavenging 
assay are shown in Table 14. The data obtained show 
relatively good correlation with sigma-meta (Figure 7). The 
benzamido and the acetamide analogs give essentially the 
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Table 14. Free Radical Scavenging Ability of Substituted 4-
Benzamido, 4-Acetamido and 4-Sulfonamido Catechols Aoainst 
Diphenylpicrylhydrazyl Radical. 
o 
H0-<0-R 
HO 
Cmpd. 
Ratea,b No. R= R'= 
------------------------------------------------------------
SOc NHS02CH3 H 0.010 .:!:. o
c 
S9b Br 0.065 .:!:. .002 
S2 so2cH3 0.121 .:!:. .oos 
SOd NHCOCH3 H 0.090 .:!:. o
c 
S9c Br 0.156 .:!:. .003 
S4b CN 0.205 .:!:. .009 
S6 NHC00 CH3 0.071 .:!:. .002 
SOb H 0.090 .:!:. .002 
S9a Br 0.152 .:!:. .012 
84a CN 0.202 .:!:. .009 
a. A minimum of three data points were taken for each test 
compound. 
b. The rate of radical scavenging is expressed as the 
initial change in absorbance/min at 51S nm. 
c. The rate of radical scavenging was identical for all 
data points collected. 
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same scavenging rates for the same substitution patterns. 
The sulfonamide analogs have lower rates of scavenging than 
the benzamido and acetamide derivatives for the same 
substitution patterns. Utilizing a dummy parameter the data 
for the sulfonamide analogs can be compared to the acetamide 
and benzamido derivatives (Figure 8). The slope of the line 
for the three series of analogs plotted is in the positive 
direction. How these analogs correlate to biological 
activity is unknown at present. In vivo studies of the 
benzamido, acetamide and sulfonamide derivatives must be 
performed and correlated to the free radical scavenging 
data. The addition of an electron withdrawing group to the 
ring wi 11 probably not result in a new class 'of ant i'tumor 
agents, but, may provide a means to optimize the inherent 
activity present. Additional amido analogs must be 
developed to determine if the electronic properties 
governing the radical scavenging process of these types of 
derivatives are important in inhibition of ribonucleotide 
reductase or anticancer effects. Comparison of the free 
radical scavenging data with the corresponding in vitro and 
in vivo shows little correlation. Although the benzamide 
analogs showed little difference in scavenging ability 
distinct differences could be observed in the biological 
assays. Catechol inhibits ribonucleotide reductase to the 
same degree as the benzamides, yet, the scavenging ability 
75 
. 40 
.35 
.� .30 
::li 
� 
w 
0 
z .25 
<( lXI 
a: 
0 
....., 
Ill 
0\ lXI 
.20 
<( 
<l 
.15 
.10 
.05 
Figure 8. Shift of The 4-Sulfonamido Catechol Data With 
Respect to the 4-Acetamido and 4-Benzamido Catechol Data • 
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of catechol is far less. N-(3,4-Dihydroxyphenyl)acetamide, 
SOd, shows the highest activity in the biological assays, 
however, the ability to scavenge a free radical is no 
greater than that of the benzamide analogs. Although the 
change in electronic parameters may influence activity to 
some degree, explanations for enhanced activity due solely 
to alterations in the reactivity of the catechol moiety are 
invalid. This would suggest that the enhanced effects 
observed in vitro and in vivo are due to direct interactions 
with the active site of the enzyme. 
Molecular Modeling Studies: 
Ribonucleotide reductase has a stabilized tyrosinyl 
free radical associated with the active site of the enzyme. 
The presence of the free radical has been shown to be 
essential for enzymatic activity. Destruction of the free 
radical leads to complete inactivation of the enzyme. 
Elford and coworkers29•33 have suggested that the 
polyhydroxybenzene derivatives inhibit ribonucleotide 
reductase by scavenging the free radical. A proposed 
mechanistic interaction between the enzyme and the natural 
substrate involves the tyrosinyl free radical abstracting 
the 3'-;6 -hydrogen of the ribose ring. Upon completion of 
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the enzymatic process the tyrosinyl free radical is 
reconstituted by allowing the hydrogen to be reabstracted 
back to the 3'-P-position. Elford,� �.,
33 have 
suggested that inhibition of ribonucleotide reductase 
involves the catechol moiety scavenging the tyrosinyl free 
radical which is located in the active site of the enzyme. 
If inhibition of ribonucleotide reductase was only dependent 
on the interaction of the catechol and the tyrosinyl free 
radical, then the data obtained from the free radical assay 
would correlate to the results obtained from the enzyme 
assay. Examination of the available biological data shows 
that significant differences can be observed for various 
substituted catechols and a correlation between free radical 
scavenging and biological results does not exist. 
Additional factors beyond the electronic parameters 
governing the scavenging of the free radical must be 
occurring. The catechol is believed to scavenge the 
tyrosinyl free radical, and the tyrosinyl free radical has 
been proposed to abstract the 3'-J' hydrogen from the ribose 
ring of the natural substrates. This would suggest that the 
catechol moiety might interact with the active site of the 
enzyme in a similar position found for the ribose ring of 
the natural substrates. As indicated from the biological 
results modifications in the 4-position of catechol can lead 
to agents with enhanced activity in vitro and in vivo. How 
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the modifications found at the 4-position interact with the 
active site is unknown. If the catechol interacts with the 
active site in a similar region as the ribose ring, it is 
possible that the 4-substituted catechols could interact 
with the active site similar to the way the natural 
substrates interact. An investigation utilizing molecular 
modeling techniques was undertaken to examine this 
possibility. Compound 80d, N-(3,4-dihydroxyphenyl)­
acetamide, shows the greatest activity, both in vitro and 
in vivo of the derivatives synthesized and was chosen as the 
model for this investigation. The molecular structures of 
80d and cytosine (Figures 9 and 10, respectively) were 
optimized using the Molecular Modeling, Analysis, and 
Display System, MMADS. The diphosphate group of the 
optimized ribonucleotide was removed for clarity when 
comparing the molecular features of the inhibitors with that 
of the natural substrates. The ribose ring of cytosine is 
in the 2'-endo conformation. The catechol moiety is 
believed to scavenge the tyrosinyl free radical. Compound 
80d has two hydroxyl groups that could be responsible for 
the discharge of the radical. When the phenolic group at 
the 1-position was superimposed on the 3'-;B hydrogen of 
cytosine, no other structural overlap between 80d and 
cytosine could be observed. When the phenolic group at the 
2-position was overlapped with the 3';B hydrogen, the 
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Figure 9. The Optimized Structure of N-(3,4-Dihydroxyphenyl)-acetamide. 
(Red= Oxygen; Blue= Nitrogen; Black= Carbon; Yellow= Hydrogen) 
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substitution at the 4-position of 80d, the amide function, 
showed similar structural overlap with the features found in 
the pyrimidine ring of cytosine (Figure 11). In Figure 11 
the aromatic ring of 80d lies in relatively the same plane 
as the quasi-planar ribose ring. The distance between the 
meta hydroxyl group and the amide nitrogen is 6.45 
angstroms. The same distance is observed for the 3'-)3 -
hydrogen and the N1-position of the cytidine ring. The 
carbonyl function of 80d can overlap the carbonyl function 
found in the cytidine moiety. Volume overlap studies show 
that cytidine displaces 132 A3, while 80d only displaces 97 
03 A . If features of the cytosine structure that can not be 
overlapped are omitted, then the volume displacement is only 
110 A3. The degree of volume overlap of 80d and cytosine 
does not change significantly when the cytidine moiety is 
placed in the anti- or syn- conformation. The overlap of 
molecular features of 80d and cytosine can occur with any 
rotation of the pyrimidine moiety. Coupled with the fact 
that the enzyme contains some conformational flexibility the 
interaction of 80d with the active site may be quite good. 
Ribonucleotide reductase is responsible for the reduction of 
both purine and pyrimidine nucleotides. The mechanism which 
governs the selectivity of the particular nucleotide to be 
reduced involves allosteric sites.15 The high affinity 
allosteric site governs which type of substrate, purine or 
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Figure 11. N-(3,4-Dihydroxyphenyl)-acetamide Superimposed 
on Cytosine. 
pyrimidine, is to be reduced. The low affinity site, which 
binds negative effectors, regulates enzymatic activity by 
acting through a feedback mechanism. Negative effectors of 
CDP reduction, dGTP, dTTP and dATP, act to inhibit the 
binding of the substrate rather than inhibiting the 
reduction of a bound substrate. Caras, � � ·· have shown 
that ATP acts as a positive effector for the reduction of 
CDP. ADP and GDP do not act competitively for reduction 
when ATP is the only positive effector present. The 
enzymatic assay utilized to examine the various analogs 
synthesized involved monitoring the reduction of CDP to 
dCDP. ATP was used as the positive effector in the assay. 
Such an assay is weighted in favor of those compounds that 
mimic CDP rather than ADP, GDP and possibly UDP. Inhibitors 
that resemble only the pyrimidines may show excellent 
activity in vivo even though their in vitro activity may 
have suggested otherwise. The pyrimidine moiety of CDP is 
planar and can be represented two dimensionally. Since the 
orientation of the pyrimidine ring, syn or anti to the 
ribose ring, does not greatly affect the overlap of the 
catechol moiety of SOd with the ribose ring of cytosine, the 
structural comparison of other modifications at 4-position 
of the catechol analogs can be compared to the features for 
the cytidine ring of cytosine. the overlap of the 4-
substituents and the pyrimidine ring of cytosine is shown in 
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Figure 12. Analogs that do not show heteroatom overlap are 
those analogs with the smallest inhibitory activity. 
Examples of this are 2!._ and 67b, 501M and 70 1M (ID50J 
respectively. Compounds that do show heteroatom overlap 
show improved inhibitory activity and improved in vivo 
activity. The terminal amino group of 67f can be oriented 
in the same position as the 4-amino group of the cytidine 
residue. Compound 91a shows enhanced activity over 2!._ or 
67b in vivo. This could be attributed to the ability of the 
carbonyl of 91a to interact with the active site at the same 
position as the carbonyl of the cytidine ring. N-(3,4-
Dihydroxyphenyl)urea, 80c, has not been tested in either the 
reduction assay or the antitumor assay. This structural 
modification should result in enhance activity in both 
assays. The 4-ureido function resembles the features of the 
cytidine ring to a greater degree than the 4-acetamido 
group. N-Acetyldopamine, 63, is a relatively weak reductase 
inhibitor. The 1050 of 63 is 400 �M; yet, 63 shows 
relatively good antitumor property (53% ILS at 600 mg/kg). 
The most likely reasons for the wide differences between 
in vitro and in vivo results is the possible metabolism of 
63 to a more active species and/or altered biodistribution. 
The 2-acetamidoethyl side chain of 63 resembles the 
structural features of uridine rather than the features 
found in the cytidine ring. Since the enzyme inhibition 
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Figure 12. Substituents Found at the 4-Position of Catechol 
Superimposed on the Cytidine Ring of Cytosine. 
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assay looks specifically at the reduction of CDP, those 
compounds that reflect a greater similarity to other natural 
substrates (UDP, ADP and GDP) may not be able to truly 
reflect their antitumor potential. Therefore, compounds 
that do not possess substantial inhibitory activity may 
still possess good antitumor properties. This may result 
from the ability of the analogs to mimic the molecular 
features of the purine nucleotides to a greater degree than 
those of pyrimidine nucleotides. 
N-(3,4-Dihydroxyphenyl)acetamide, 80d, was also 
compared with guanosine utilizing molecular modeling 
techniques. Figure 13 shows the optimized structural of 
guanosine and the overlap of 80d and guanosine are shown in 
Figure 14. The distance between the 3' j3 hydrogen and the 
nitrogen at the 9-position is, as expected, 6.45 A. The 
aromatic ring of 80d lies in the same plane as the quasi 
planar ribose ring. Only the nitrogen of the 4-amido group 
is shown to overlap the features of the guanine moiety. The 
purine ring of guanosine is planar and can also be 
represented two dimensionally. The substituents found at 
the 4-position of catechol are compared to the purine ring 
of guanosine. The orientation of these substituents with 
the molecular features of the purine ring can be more 
complex than is the case with the pyrimidine ring. The 
guanine moiety being comprised of two rings fused together, 
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Figure 14. N-(3,4-Dihydroxyphenyl)-acetamide Superimposed on the 
Structure of Guanosine. 
allows different overlap patterns to be observed. 
Comparison of some substituents found at the 4-position of 
catechol and the guanine ring of GDP are shown in Figures 
15(a,b). Simple amides such as 51 and 67b do not show 
heteroatom overlap. Other compounds like 67f can be 
superimposed onto the guanine ring in two different 
orientations. Adenosine is closely related to the structure 
of guanosine. The terminal amino group of � can be placed 
in a similar position for the 6-amino function in the 
adenine ring. The observed antitumor activity of 67f may be 
a result of the compound's ability to bind with the enzyme 
regardless of which type of positive effector is controlling 
substrate specificity. N-Acetyldopamine can be overlapped 
with some of the molecular features of the guanine ring. 
The urea function of SOc does show some similarity to the 
features of the guanine ring. As stated before this analog 
is expected to show improved activity for both enzyme 
inhibition and antitumor activity. 
The topography of the active site of ribonucleotide 
reductase is unclear at present. It is known that the 
active site contains several sulfhydryl groups. The exact 
arrangement of these groups is unknown. The structural 
features which govern the binding of the purine and 
pyrimidine rings are also unclear. By comparing the 
inhibitors developed with the features of the natural 
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Figure 15a. Substituents Found at the 4-Position of 
Catechol Superimposed on the Guanine Ring of Guanosine. 
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Figure 15b. Substituent Found at the 4-Position of 
Catechol Supeiimposed on the Guanine Ring of Guanosine. 
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substrates, it may be possible to deduce some of the 
molecular topography of the enzyme's active site. 
Additional analogs designed specifically to mimic the purine 
and pyrimidine nucleotides are needed to more accurately 
define structure activity relationships for enzyme 
inhibition and/or antitumor activity. 
Several of the synthesized derivatives have shown both 
enzymatic and antineoplastic activity. Elford and coworkers 
have suggested that a correlation exists between the rate of 
free radical scavenging and activity in vivo.33 The 
correlation was based on the fact that by placing an 
additional hydroxyl group on the aromatic ring both free 
radical scavenging and in vivo activity would be enhanced. 
Indeed this may be true. Since the phenolic moiety is the 
group that is responsible for the scavenging of the free 
radical, an increase in the number of hydroxyl groups might 
simply enhance the opportunity for radical scavenging. To 
more accurately determine the interaction of the 
polyhydroxybenzene moiety's ability to scavenge a free 
radical, various 4-substituted catechols were examined for 
their ability to scavenge a free radical. Mixed results 
were obtained when the data obtained was plotted against 
various Hammett parameters. Two different relationships 
appear to be present, one for the 4-amido catechols, 
reverse-amides, and one for the remaining data. High 
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correlation with electronic parameters were obtained for 
both sets of data when analyzed separately. The slope of the 
line for the reverse-amides is opposite that found for the 
rest of the data. This would suggest that the mechanism 
involved in the free radical scavenging is different between 
the two sets of derivatives. Regardless of this difference 
the data obtained from the free radical scavenging assay 
does not correlate well with the observed in vivo results. 
According to the data obtained from the free radical 
scavenging assay compounds such as 63, N-acetyldopamine, and 
91a, 2-(3,4-dihydroxyphenyl)acetamide, should show less 
activity in vivo than that of 95, 3,4-dihydroxybenzamide. 
This is not the case. All the N-substituted 3,4-
dihydroxybenzamide derivatives showed the same free radical 
scavenging ability. Marked difference in activity could be 
seen for the various N-substituted amides in vivo. Compound 
67f is the most potent N-substituted dihydroxybenzamide 
tested, whereas, compounds such as 95, 67b and 67c are 
relatively weak or inactive. The most active compound of 
the analogs synthesized was 80d. This reverse-amide analog 
showed the same ability to scavenge free radicals as the 
benzamide analogs. The free radical assay cannot be 
utilized as a method to predict in vitro activity. Reversal 
of the orientation of the amide bond, as found in 80d 
compared to 95, has resulted in a 10 fold increase in enzyme 
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inhibition. Molecular modeling was utilized to examine the 
relationship of 80d with CDP and GDP, two of the natural 
substrates reduced by ribonucleotide reductase. The amido 
function overlaps the molecular features found in the 
cytidine ring of CDP to a relatively high degree. 
Generally, the most active enzyme inhibitors synthesized 
appeared to structurally resemble the molecular features of 
the cytidine ring in CDP. Derivatives that showed good 
enzyme inhibition generally showed good antitumor activity. 
There are cases where good antitumor activity is observed 
whereas the results of enzyme inhibition might have 
suggested otherwise. An example of this is N­
acetyldopamine, 63. The ID50 of 63 observed in the enzyme 
assay is 400 �M and 63 gives an 53% increase in life span of 
treated mice, versus control mice, at a dose of 600 mg/kg. 
Discrepancies between enzyme data and antitumor results may 
arise from the protocol used to determine inhibitory 
activity or distribution/metabolism effects. The enzyme 
assay monitors the reduction of CDP to dCDP utilizing ATP as 
a positive effector. GDP and ADP do not compete with CDP 
for reduction when ATP is the only positive effector 
present. Conformational change of the active site has been 
proposed to account for this selectivity. Derivatives that 
structurally resemble GDP, ADP or possible UDP may be 
unfairly judged in the enzymatic assay. N-Acetyldopamine, 
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63, appears to resemble the features of the guanine ring of 
GDP and the uridine ring of UDP more than the cytidine ring. 
This may explain, in part, the difference in activity 
obser�ed for in vitro and in vivo assays. The presence of a 
methylene may decrease the free radical scavenging ability 
of the catechol nucleus. 
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CONCLUSIONS 
The results obtained from the various assays and 
molecular manipulations suggest that the compounds that show 
the greatest activity, structurally resemble the natural 
substrates of reduction. This would imply that the 
poly hydroxybenzene analogs interact with the active site of 
the enzyme similar to that of the natural substrates. 
Reversal of the amide bond, seen in 80d, results in a 
significant increase in activity. The ability of the 
compound to scavenge a free radical is not diminished by 
such a molecular modification. The acetamide function 
appears to be the optimized structural feature of this 
study. Placement of an ami'ne function 5 atoms from the 
aromatic ring also appears to enhance activity. The 3-
(N' ,N'-dimethylamino)-N-(3,4-dihydroxyphenyl)propanamide, 
which contains the amine and reversed-amide features, should 
be synthesized and tested in both in vitro and in vivo 
assays. Molecular modeling suggests that those compounds 
that structurally resemble .the cytidine ring of CDP should 
show good activity in both the in vitro and in vivo assays. 
Replacement of the methyl group in 80d with a NH2 group 
should show an increase in activity. This compound, 80c, 
has been synthesized and is currently being examined. 
Results for this analog are unavailable at this time. 
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Several other compounds synthesized are awaiting testing in 
both the enzyme and antitumor assays. Several of the 
compounds synthesized have been evaluated by the National 
Cancer Institute of the National Institutes of Health 
(NCI/NIH). Additional work is needed to explore the 
structural relationship of the polyhydroxybenzene 
derivatives and the structural features of the natural 
substrates. 
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EXPERIMENTAL 
General Methods: 
Melting points were determined on a Thomas-Hoover 
melting point apparatus (uncorrected). Infrared Spectra were 
obtained with a Beckman Acculab 8 grating spectrophotometer. 
Proton NMR spectra were obtained with a Jeol-FX90Qll Fourier 
Transform Multinuclear spectrometer. Samples were prepared 
in 5 mm NMR tubes at approximately 20 mg/ 0.4 mL deuterated 
solvent. Solvents utilized were d-6 DMSO or CDC13. TMS 
(tetramethylsilane) or non-deuterated DMSO were used as 
reference solvents. Deuterated solvent and reference 
solvent are given for each analog examined (ie. d6-
DMSO,DMSO). Analysis of free radical scavenging was 
obtained on a Beckman UV-Vis Spectrophotometer Model 25. 
The method of analysis employed is analogous to the method 
described by Venker and Herzmann48 The radical scavenging 
ability of the substituted catechols was determined by 
measuring the destruction of the stable free radical 
diphenylpicrylhydrazyl, in the presence of the test 
compound. The absorbance at 518 nm of a 95�M solution of 
diphenylpicrylhydrazyl free radical in acetone was 
monitored. The test compound was added at a final 
concentration of 47.5�M and the change of absorbance at 
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518 nm with respect to time was recorded. Each compound was 
tested a minimum of three times. The free radical 
scavenging ability is expressed �s the initial change in 
rate of absorbance/min. 
Chemical Synthesis: 
Methyl 3,4,5-Trihydroxybenzoate 49: 3,4,5-
trihydroxybenzoic acid, 58, (50.0 g, 294 mmol) was dissolved 
in methanol (250 mL) with a catalytic amount of sulfuric 
acid (2 mL) present. The solution was heated at reflux for 
16 h, concentrated under reduced pressure to 50 mL and 
poured into water (300 mL). The pH of the solution was 
adjusted to 7.0. The solid was removed by filtration and 
placed in 50% aqueous methanol (200 mL). The mixture was 
heated until dissolved and filtered through carbon. The 
filtrate was cooled, and the resulting precipitate was 
removed by filtration yielding 45.72 g (84%) of 49 as a 
white solid, mp 201°C [lit. (50) mp 199-202°C]. IR(KBr) 
cm-1 1670 (C=O, ester). 1H NMR (d6-DMSO, DMSO) 3.74 ppm 
(s,3,CH3); 6.93 (s,2,ArH); 8.92 (s,1,ArOH); 9.25 (s,2,Ar0H). 
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N-Benzyl-3,4,5-trihydroxybenzamide 64a: Benzylamine 
(16.0 g, 149 mmol) was heated neat to 100°
.
C. To this was 
added slowly methyl 3,4,5-trihydroxybenzoate 49 (16.0 g, 
86.9 mmol) . The mixture was heated at 180°C for 2.5 h, 
cooled and poured into water (400 mL). The pH of the 
solution was adjusted to 4.0. ·The solution was heated until 
dissolved and filtered through carbon. The filtrate was 
cooled, and the resulting precipitate was removed by 
filtration yielding 4. 18 g (19%) of 64a as a white solid, 
188-191°C. IR (KBr) -1 1605 (C=O, amide) . 1H NMR (d6-em 
DMSO, DMSO) 4.45 ppm (d, 2 ,CH2), 6.95 (s,2,ArH), 7.3 
(s,5,ArH) , 8.55-8.75 (t,1,amide NH). 
Anal. Calculated for c14H13No4 X 1H20: C, 60.64; H, 
5.45; N, 5.05. Found: C, 60.88; H, 5.52; N, 5.04. 
N- (2-Phenylethyl) -3,4,5-trihydroxybenzamide 64b: 
mp 
Phenethylamine (12.0 g, 99.2 mmol) was heated neat to 100°C. 
To this was added slowly methyl 3,4,5-trihydroxybenzoate � 
(9.74 g, 529 mmol) . The mixture was heated to reflux for 
22.5 h, cooled and washed with ethyl acetate (2 x 20 mL) . 
The residue was poured into water (100 mL), and the pH was 
adjusted to 2.0. The solution was heated until dissolved 
and filtered through carbon. The filtrate was concentrated 
under reduced pressure until precipitation occurred. The 
solution was cooled, and the precipitate was removed by 
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filtration yielding 4.95 g (34%) of 64b as a white solid, mp 
128-130°C. IR(KBr) cm-1 1605 (C=O, amide). 1H NMR (d6-
DMSO, DMSO) 2.70-2.95 ppm (t,2,Ar-CH2-CH2), 3.3-3.7 (m,2,NH­
CH2-CH2), 6.9 (s,2,ArH), 7.3 (s,5,ArH), 8.1-8.3 (t,1, 
amide NH). 
Anal: Calculated for c15H15No4: C, 65.92; H, 5.53; N, 
5.13. Found: C, 65.89; H, 5.57; N, 5.10. 
N-(2-Hydroxyethyl)-3,4,5-trihydroxybenzamide 64c: 2-
Aminoethanol (16.0 g, 262 mmol) was heated neat to 100°C. 
To this was added slowly methyl 3,4,5-trihydroxybenzoate 49 
(18.0 g, 97.8 mmol). The mixture was heated at 180°C for 
2.5 h, cooled and washed with ethyl acetate (2 x 20 mL). 
Water (100 mL) was added to the residue, and the pH was 
adjusted to 4.0. The solution was heated until dissolved 
and filtered through carbon. The filtrate was cooled, and 
the resulting precipitate was removed by filtration yielding 
14.6 g (70%) of 64c as a white solid, mp 219-221°C [ 1 it. 
(51) 219-220.5°C]. IR(KBr) -1 1600 (C=O, amide). 1H mp em 
NMR (DMSO) 3.24-3.48 ppm (m,4,CH2CH2-0H), 6.84 (s,2,ArH), 
7.98 (t,1,amide NH), 7.21 (s broad,3,ArOH). 
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N-(3-Hydroxypropyl)-3,4,5-trihydroxybenzamide 64d: 
This compound was synthesized analogously to compound �: 3-
Aminopropanol (16.6 g, 221 mmol) was heated neat to 100°C. 
To this was added slowly methyl 3,4,5-trihydroxybenzoate � 
(18.2 g, 98.9 mmol). The mixture was heated at 170°C for 2 
h, cooled and washed with ethyl acetate (2 x 20 mL). Water 
(100 mL) was added to the residue, and the pH was adjusted 
to 4.0. The solution was heated until dissolved and 
filtered through carbon. The filtrate was cooled, and the 
resulting precipitate was removed by filtration yielding 
7.45 g (33%) of 64d as a white solid, mp 148-151°C. IR(KBr) 
-1 6 1 em 1 00 (C=O, amide). H NMR (d6-DMSO, DMSO) 1.47-1.76 ppm 
(m,2,CH2-CH2-CH2), 3.13-3.5 (m,5,NH-CH2-CH2-CH2-0H), 6.8 
(s,2,ArH), 8.0 (t,3,amide NH), 8.3-9.3 (broad,3,Ar0H). 
Anal: Calculated for c10H13No5: C, 52.86; H, 5.77; N, 
6.16. Found: C, 52.65; H, 5.82; N, 6.12. 
N,N-Dimeihyl-3,4,5-trihydroxybenzamide 65: 3,4,5-
Trihydroxybenzoic acid, 57, (8.50 g, 50 mmol) was added to 
ethyl acetate (100 mL). T� this solution was added thionyl 
chloride (7 mL, 95 mmol). The mixture was heated at reflux 
for 6 h. The solvent and excess thionyl chloride were 
removed by evaporation under reduced pressure. The 
resulting oil was then dissolved in 100 mL toluene. A 
portion of this crude acid chloride solution (50 mL) was 
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placed on an ice bath. To this was added dropwise 20 mL 
dimethylamine in toluene (0.2 g/mL). After the addition was 
complete the reaction mixture was stoppered and allowed to 
stir at room temperature for 48 h.· The solution was 
filtered, and the filtrate was concentrated to an oil under 
reduced pressure. Water (20 mL) was added to the oil. 
Cooling of the solution gave an off-white solid, which when 
recrystallized from water yielded 750 mg (40%) of 65 as a 
white solid, mp 175-176°C. IR(KBr) cm-
l 
1595 (C=O, amide). 
1 H NMR (d6-DMSO, DMSO) 3.0 ppm (s,6,CH3), 6.45 (s,2,ArH), 
8.3-9.5 (broad,3,Ar0H). 
Anal: Calculated for c9H11No4 X 1H2_<?: C, 5�.23; H, 
6.09; N, 6.51. Found: C, 50.23; H, 6.06; N, 6.44. 
Methyl 3,4-dihydroxybenzoate 46: 3,4-Dihydroxybenzoic 
acid, 66, (50.0 g, 324 mmol) was dissolved in methanol (200 
mL) with a catalytic amount of sulfuric acid (2 mL) present. 
The mixture was heated at reflux for 24 h, concentrated 
under reduced pressure to 50 mL and poured into water (200 
mL). The pH of the solution was adjusted to 7.0. The 
precipitate was removed by filtration yielding 49.56 g (90%) 
of 46 as a white solid, mp 133-134°C [lit. (52) mp 133-
1340C]. lR(KBr) 1690 cm-
l 
(C=O, ester). 1H NMR (d6-DMSO, 
DMSO) 3.76 ppm (s,3,CH3); 6.74-7.35 (m,3,ArH); 8.9-9.9 
(broad,2,Ar0H). 
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N-(2-Hydroxyethyl)-3,4-dihydroxybenzamide 67a: 2-
Aminoethanol (8.0 g, 131 mmol) was heated neat to 100°. To 
this was added slowly methyl 3,4-dihydroxybenzoate, 46, 
(10.0 g, 59 mmol). The mixture was heated at reflux for 12 
h, cooled and dissolved in water (100 mL). The pH of the 
solution was adjusted to 2.0. The solution was filtered 
through carbon, and the filtrate was concentrated to 50 mL 
under reduced pressure. Cooling of the solution resulted in 
precipitation of an off-white solid. The solid was removed 
by filtration and recrystallized in 50 mL isopropanol/ 
acetone/ethyl acetate (12:3:35) yielding 7.56 g (64%) of 76a 
as a white solid, mp 154-155°C. IR(KBr) cm-1 1605 (C=O, 
1 amide). H NMR (d6-DMSO, TMS) 3.53 (t,2,-CH2-N); 4.01 
(t,2,-CH2-0l; 6.80-7.40 (m,3,ArH); 8.15 (broad s,1,amide 
NH); 8.4-9.7 (broad,3,ArOH and aliph-OH). 
Anal: Calculated for c9H11No4: C, 54.81; H, 5.62; N, 
7.10. Found: C, 54.64; H, 5.67; N, 7.06. 
3,4-Diacetoxybenzoic acid 68: 3,4-Dihydroxybenzoic 
acid, 66, (75.0 g, 487 mmol) was suspended in acetic 
anhydride (250 mL) and heated at reflux for 24 h. The 
solution was concentrated to an oil under reduced pressure. 
Water (300 mL) was added to the oil and the solution was 
heated at boiling for 30 min. The solution was cooled, and 
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the resulting precipitate was removed by filtration yielding 
111 g (95%) of 68 as a off-white solid, mp 156-157°C [lit. 
0 -1 (53) mp 157-158 C). IR(KBr) em 1780 (C=O, ester, 
aliphatic); 1690 (C=O, ester,aromatic). 1H NMR (d6-DMSO, 
DMSO) 2.23 ppm (s,6,CH3); 7.35-7.93 (m,3,ArH). 
3,4-Diacetoxybenzoyl chloride 69: 3,4-diacetoxybenzoic 
acid, 68, (20.0 g, 84 mmol) was suspended in ethyl acetate 
(100 mL). Thionyl chloride (6.70 mL, 92 mmol) was added, 
and the mixture was heated at reflux for 6 h. The solution 
was concentrated under reduced pressure to an oil, added to 
petroleum ether and cooled. The resulting precipitate was 
removed by filtration through a glass filter yielding 20.1 g 
(85%) of 69 as a tan solid, mp 54-55°C [lit. (54) mp 55°C). 
IR(KBr) cm-1 1780 (C=O, ester); 1770 (C=O, acid chloride). 
1H NMR (d6-DMSO, DMSO) 2.30 ppm (s,6,CH3); 7.34-8.07 
(m,3,ArH). 
N-Benzyl-3,4-dihydroxybenzamide 67b: 3,4-
Diacetoxybenzoyl chloride, 69, (2.99 g, 11.6 mmol) was 
dissolved in benzene (50 mL). To this was added dropwise 
benzylamine (2.51 g, 23.4 mmol) dissolved in benzene (20 
mL). The mixture was heated slightly for 20 min and 
filtered warm. Pyrrolidine (2.0 g, 28 mmol) was added to 
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the filtrate and heated slightly for 15 min. The solution 
was concentrated to an oil under reduced pressure and poured 
into water (50 mL). The pH of the solution was adjusted to 
2.0. The solution was cooled, and the resulting precipitate 
was removed by filtration yielding 2.21 g (78%) of 67b as a 
white solid, mp 191°C. IR(KBr) cm-1 1590 (C=O, amide). 1H 
NMR (d6-DMSO, TMS) 4.39-4.46 ppm (d,2,NH-CH2-Ar); 6.72-7.35 
(m,8,ArH); 8.7 (t,1,amide NH); 9.0-9.6 (broad,2,Ar0H). 
Anal: Calculated for c14H13No3: C, 69.12; H, 5.39; N, 
5.76. Found: C, 68.86; H, 5.45; N, 5.69. 
N-(2-Phenylethyl)-3,4-dihydroxybenzamide 67c: 3,4-
Diacetoxybenzoyl chloride, 69, (3.23 g, 12.6 mmol) was 
dissolved in benzene (50 mL). To this was added dropwise 2-
phenylethylamine (3.0 g, 24 mmol) dissolved in benzene (20 
mL). The mixture was heated slightly for 15 min and 
filtered. The filtrate was concentrated to an oil under 
reduced pressure, and water (100 mL), containing sodium 
carbonate (6.0 g, 56 mmol), was added. The mixture was 
heated until all residues were dissolved. The solution was 
acidified to pH 2.0 and cooled. The crude product was 
removed by filtration and dissolved in 95% ethanol (50 mL). 
The solution was filtered through carbon. Water was added 
until precipitation occurred. The precipitate was removed 
by filtration yielding 1.62 g (50%) of 67c as a white solid, 
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mp 138-140°C. IR(KBr) 1600 cm-1 (C=O, amide). 1H NMR (d6-
DMSO, TMS) 2.73-2.89 ppm (t,2,CH2-Ar); 3.32-3.55 (q,2,NH­
CH2); 6.71-7.24 (m,8,ArH); 8.15-8.30 (t,1,amide NH); 8.92 
(broad s,2,ArOH). 
Anal: Calculated for c15H15N03: C, 70.02; H, 5.87; N, 
5.44. Found: C, 69.96; H, 5.91; N, 5.41. 
N-(3-Phenylpropyl)-3,4-dihydroxybenzamide 67d: 3,4-
Diacetoxybenzoyl chloride, 69, (3.98 g, 15.5 mmol) was 
dissolved in benzene (50 mL). To this was added dropwise 3-
phenylpropylamine (4.2 g, 31 mmol) dissolved in benzene (20 
mL). The mixture was heated slightly for 15 min and 
filtered. Pyrrolidine (2.5 g, 35 mmol) was added to the 
filtrate and heated slightly for 20 min. The solution was 
concentrated to an oil under reduced pressure. The oil was 
dissolved in 50% aqueous acetone (50 mL) and filtered 
through carbon. The filtrate was concentrated under reduced 
pressure until a precipitate formed. The precipitate was 
removed by filtration yielding crude 67d. The solid was 
again placed in 50% aqueous acetone and the previous method 
of purification was repeated yielding 2.26 g (54%) of 67d as 
a white solid, mp 144-145°C. IR(KBr) cm-1 1620 (C=O, 
amide). 1H NMR (d6-DMSO, TMS) 1.63-1.90 ppm (m,2,CH2-CH2-
CH2); 2.52-2.69 (t,2,CH2-CH2-Ar); 3.11-3.38 (q,2,NH-CH2-
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CH2); 6.70-7.22 (m,8,ArH); 8.26 (broad s,1,amide NH); 9.56 
(broad s,2,Ar0H). 
Anal: Calculated for c16H17No3: C, 70.83; H, 6.32; N, 
5.16. Found: C, 70.69; H, 6.36; N, 5.14. 
Bis-N-(3,4-dihydroxybenzoyl)-ethylenediamine 67e: 3,4-
Diacetoxybenzoyl chloride, 69, (12.0 g, 46.8 mmol) was 
dissolved in benzene (50 mL). To this was added dropwise 
ethylenediamine (2.8 g, 46 mmol) dissolved in benzene (20 
mL). The mixture was heated slightly for 15 min and 
filtered. The solid was placed in water (100 mL), and the 
pH of the solution was adjusted to 11.0 with 50% sodium 
hydroxide. The solution was warmed and the pH checked 
periodically. Additional base was added to maintain pH at 
11.0. When the solution required no further addition of 
base, the solution was acidified to pH 1.0 with concentrated 
HCl. The resulting precipitate was removed by filtration 
and dissolved in 70% aqueous acetone (50 mL). The solution 
was filtered through carbon, and the filtrate was poured 
onto crushed ice. The precipitate was removed by filtration 
yielding 4.68 g (30%) of 67e as a white solid, mp 255-256°C. 
lR(KBr) cm-
1 
1630 (C=O, amide). 1H NMR (d6-DMSO, DMSO) 3.35 
ppm (s,4,CH2); 6.70-7.20 (m,6,ArH); 8.23 (s,2,amide NH); 
9.09-9.40 (d,4,Ar0H). 
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Anal: calculated for c16H16N2o6: C, 57.83; H, 4.85; 
N, 4.83. Found: C, 57.63; H, 4.88; N, 4.82. 
N-(2-(N' ,N'-Dimethylamino)ethyl)-3,4-diacetoxy 
benzamide.HCl 70f: 3,4-Diacetoxybenzoyl chloride, 69, (6.0 
g, 23.5 mmol) was placed in ethyl acetate (100 mL) and 
cooled to 0°C. 2-(N,N-dimethylamino)ethylamine (2.08 g, 
23.5 mmol) dissolved in ethyl acetate (25 mL) was added 
dropwise to the acid chloride solution. After the addition 
was complete the mixture was allowed to stir at room 
temperature for 45 min. The crude product was collected by 
filtration and then recrystallized from hot ethanol/acetic 
acid (100 mL, 50:1). Filtration of the precipitate of the 
cooled solution yielded 6.1 g (75.5%) of 70f as an of white 
solid, mp 186-8°C. IR(KBr) cm-1 2740 (amine.HCl); 1770 
(C=O, ester); 1605 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 2.29 
(s,6,-C(O)CH3l; 2.78 (s,6,N-CH3); 3.32-3.58 (m,4,-NH-CH2-
CH2-N); 7.23-7.43 (m,3,ArH); 8.41-8.57 (t,1,NH). 
Anal.: calculated for c15H20N2o5.HC1: C, 52.25; H, 
6.13; N, 8.12; Cl, 10.28. Found: C, 52.11; H, 6.11; N, 
8.02. 
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N-(2-(N' ,N'-Dimethylamino)ethyl)-3,4-dihydroxy 
benzamide.HCl 67f: ?Of ( 3.0 g, 8.7 mmol) was placed in 
water (20 mL). The pH of the aqueous solution was adjusted 
to 11 by the addition of 50% sodium hydroxide. Additional 
base was added as the pH of the solution lowered. The 
reaction was complete when the solution maintained a pH of 
11 for 10 min. The solution was adjusted to a pH of 2 with 
concentrated. HCl. The solvent was removed under reduced 
pressure leaving a solid residue. Ethanol (30 mL) was added 
to the residue and heated to boiling. The solution was 
filtered hot. The filtrate was cooled and the resulting 
precipitate was collected by filtration yielding 1.99 g of 
67f as a white solid, mp 209-11°C. IR(KBr) cm-1 2740 
(amine.HCl); 1595 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 2.81 
ppm (s,6,N-CH3); 3.32-3.56 (m,4,(CH2)2); 7.26-7.51 
(m,3,ArH); 8.38-8.56 (t,1,NH); 9.23-9.48 (d,2,ArOH). 
Anal.: calculated for C11H16N2o3.HC1: C, 50.67; H, 
6.57; N, 10.74; Cl, 13.59. Found: C, 50.43; H, 6.61; N, 
10.66; Cl, 13.50. 
1-(2-(3,4-Dihydroxybenzamido)-acetyl)-pyrrolidine 67g: 
3,4-Diacetoxybenzoyl chloride, 69, (7.37 g, 28.8 mmol) was 
placed in tetrahydrofuran (100 mL) at 5°C. Benzyl glycinate 
p-toluenesulfonate salt (9.0 g, 26.7 mmol) and triethylamine 
(7.5 mL) were added to the acid chloride solution. The 
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mixture was allowed to stir for 30 min at 5°C and then at 
room temperature for 24 h. The mixture was filtered and the 
filtrate concentrated to an oil under reduced pressure. 
Pyrrolidine (30 mL) was added to the oil and the solution 
was heated to boiling for 10 min and then allowed to stir at 
room temperature for 5 h. The solution was concentrated to 
an oil under reduced pressure. Water (50 mL) was added to 
the oil, the pH of the solution adjusted to 1 and the 
solution was cooled. The crude product was collected by 
filtration and recrystallized from methanol to yield 4.8 g, 
(64.1%) of §I[ as a white solid, mp 210-2°C. lR(KBr) cm-1 
1610 (C=O, amide). 1H NMR (d6-DMSO,TM�) 1.80-2.05 ppm 
(m,4,CH2-CH2-CH2-CH2); 3.35-3.70 (m,4,N-CH2-CH2); 4.04-4.15 
(d,2,NH-CH2-C=0); 6.85-7.45 (m,3,ArH); 8.20-8.40 (t,1,NH); 
9.45 (s,2,Ar0H). 
Anal.: calculated for: c13H16N2o3 X 1H20: C, 55.31; 
H, 6.43; N, 9.92. Found: C, 55.27; H, 6.44; N, 9.89. 
N,N-Dibenzyl-3,4-dihydroxybenzamide 71: 3,4-
Diacetoxybenzoyl chloride, 69, (3.0 g, 11 mmol) was 
dissolved in benzene (50 mL). To this was added dropwise 
dibenzylamine (4.6 g, 23 mmol) dissolved in benzene (20 mL). 
The mixture was heated to boiling and filtered hot. 
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Pyrrolidine (2.6 g, 36 mmol) was added to the filtrate and 
heated to boiling for 15 min. The solution was concentrated 
to an oil under reduced pressure. Water (100 mL) was added 
to the oil and the pH was adjusted to 2.0. The solution was 
heated to boiling and the water was decanted from the 
undissolved oil. Fresh water (100 mL) was added to the oil, 
and again the solution was brought to a boil and decanted. 
The residue was dissolved in methanol, and precipitation 
occurred with the addition of water. The crude product was 
removed by filtration and dissolved in 70% aqueous acetone 
(50 mL). The solution was filtered through carbon, and the 
filtrate poured onto crushed ice. The precipitate was 
removed by filtration yielding 2.64 g (68%) of Z! as a white 
solid, mp 153-155°C. IR(KBr) cm-1 1610 (C:O, amide). 1H 
NMR (d6-DMSO, DMSO) 4.48 ppm (s,4,CH2-Ar); 6.75-7.39 
(m,13,ArH); 9.18-9.32 (d,2,Ar0H). 
Anal: Calculated for c21H19N03: C, 75.66; H, 5.74; N, 
4.20. Found: C, 75.53; H, 5.75; N, 4.20. 
3,4-Dibenzyloxybenzoic acid 72: Ethyl 3,4-
dihydroxybenzoate, 46, (5.4 g, 29.8 mmol) was placed in n­
butanol (100 mL). To this were added benzyl bromide (7 mL, 
58.8 mmol) and anhydrous potassium carbonate (20 g, 144.9 
mmol). The mixture was heated at reflux for 24 h. To the 
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mixture were added 50% sodium hydroxide (20 mL) and water 
(100 mL) and the solution was heated at reflux for 1 h. The 
solvent was removed under reduced pressure until a 
precipitate formed. The pH of the mixture was adjusted to 1 
with concentrated HCl. The solid was removed by filtration 
and recrystallized from isopropanol to yield 7.82 g (78.5%) 
of� as a white solid, mp 179-81°C [lit. (41) mp 182°C]. 
IR(KBr) cm-1 1690 (C=O, acid). 1H NMR (d6-DMSO,DMSO) 5.45-
5.55 (d,4,CH2); 7.40-8.05 (m,13,ArH). 
Benzyl N-(3,4-dibenzyloxybenzoyl)-glycinate 73a: 72 
(6.25 g, 18 mmol) was placed in chloroform (150 mL). 
Thionyl chloride (2.2 mL, 30 mmol) was added and the mixture 
was heated at reflux for 1.5 h. The solution was 
concentrated to an oil under reduced pressure. The oil was 
dissolved in ethyl acetate (100 mL). Benzyl glycinate p­
toluenesulfonate salt (6.7 g, 18 mmol) was added and the 
mixture was heated at reflux for 30 min; cooled and 
extracted several times with dilute hydrochloric acid. The 
organic layer was concentrated to an oil under reduced 
pressure. Water (100 mL) was added to the oil and heated to 
boiling for 10 min. The solution was cooled and the 
precipitate collected by filtration to yield 7.9 g (91%) of 
73a as a white solid, mp 107-9°C. IR(KBr) 1690 cm-
1 
(C=O, 
ester); cm-1 1600 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 4.00-
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4.07 (d,2,-NH-CH2); 5.16-5.20 (m,6,Ar-CH2-0l; 7.10-7.65 
(m,18,ArH). 
Anal.: calculated for c30H27No5: C, 74.82; H, 5.65; 
N, 2.90. Found: C, 74.87; H, 5.35; N, 3.01. 
N-(3,4-Dihydroxybenzoyl)glycine 74a: 73a (7.0 g, 14.5 
mmol) was debenzylated under hydrogenating conditions: 73a 
was placed in methanol (100 mL) in the presence of palladium 
(10%) on carbon (250 mg). After hydrogenation the solution 
was filtered by gravity twice to remove catalyst. The 
filtrate was concentrated to an oil under reduced pressure. 
To the oil was added petroleum ether (60-90°C boiling, 50 
mL). The solution was heated to boiling until 
crystallization occurred. The precipitate was collected by 
filtration yielding 2.86 g (93%) of 74a as a white solid, mp 
223°C [lit. (40) mp 216-220 °C]. lR(KBr) 1695 cm-1 (C=O, 
acid); cm-1 1605 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 3.91-
3.97 (d,2,-NH-CH2); 6.82-7.41 (m,3,ArH); 8.11-8.35 (t,1,NH); 
9.44-9.72 (d,2,ArOH). 
Ethyl N-(3,4-dibenzyloxybenzoyl)-glycinate 73b: 3,4-
Dibenzyloxybenzoic acid, 72, (16.0 g, 47.9 mmol) was placed 
in chloroform (150 mL). Thionyl chloride (4.0 mL, 
54.8 mmol) was added and the mixture was heated at reflux 
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for 3.5 h. Ethyl glycinate hydrochloric salt (8.0 g, 
57.6 mmol) was added to the acid chloride solution. Excess 
triethylamine. was added slowly to the mixture. The mixture 
was stirred at room temperature for 1.5 h. The mixture was 
extracted several times with dilute hydrochloric· acid. The 
organic layer was concentrated to an oil under reduced 
pressure. Water (100 mL) was added to the oil and heated to 
boiling for 10 min. The solution was cooled and the 
precipitate was collected by filtration yielding 14.61 g 
(73%) of 73b as a white solid, mp 145-6°C. IR(KBr) cm-1 
1695 (C=O, ester); 1605 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 
1.12-1.28 (t,3,-CH2-CH3); 3.94-4.23 (m,4,-NH-CH2-a�d -O-CH2-
CH3); 5.17-5.21 (d,4,Ar-CH2-0); 7.10-7.60 (m,13,ArH); 8.72-
8.84 (t,1,NH). 
Anal.: calculated for c25H25No5: C, 71.58; H, 6.00; 
N, 3.33. Found: C, 71.23; H, 6.24; N, 3.15. 
Ethyl N-(3,4-dihydroxybenzoyl)-glycinate 74b: 73b 
(12.0 g, 28.6 mmol) was debenzylated under hydrogenating 
conditions. Palladium (10%) on carbon (2.0 g) was used as 
catalyst. The solvent employed was methanol (100 mL). 
After the appropriate amount of hydrogen was taken up by the 
reaction the solution was filtered by gravity twice to 
remove all catalyst. The filtrate was concentrated to an 
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oil under reduced pressure. To the oil was added water 
(100 mL). The solution was allowed to stir on an ice ice 
bath for three h. The precipitate was collected and 
recrystallized from water yielding 4.65 g C94%) of 74b as a 
white solid, 158-60°C [lit. (55) mp 160°C.) IR(KBr) cm-1 
1695 (C=O, acid); 1610 (C=O,- amide). 1H NMR (d6-DMSO,DMSO) 
1.11-1.27 (t,3,-CH2-CH3l; 3.88-4.21 (m,4,-NH-CH2 and O-CH2-
CH3); 6.72-7.35 (m,3,ArH); 8.48-8.60 (t,1,NH); 9.14-48 
( d, 2, ArOH) . 
1,2-Dibenzyloxybenzene 76a: Catechol, 75a, (10 g, 
90.9 mmol) was placed in n-butanol (70 mL). To this were 
added anhydrous potassium carbonate (30 g, 217 mmol) and 
benzyl chloride (28 mL, 205 mmol). The mixture was heated 
at reflux under a nitrogen atmosphere for 40 h. The solvent 
was removed under reduced pressure until a precipitate 
formed. Water (100 mL) and 50% sodium hydroxide (2 mL) were 
added and the mixture was extracted with ethyl acetate (3 x 
60 mL). The organic layers were combined and extracted with 
dilute. HCl (3 x 30 mL). The organic layer was dried with 
magnesium sulfate and concentrated to an oil under reduced 
pressure. To the oil was added methanol (100 mL). Upon 
cooling a precipitate formed which was collected by 
filtration yielding 23.73 g (90%) of 76a as a white solid, 
mp 64°C [lit. (42) mp 62°C. IR(KBr) cm-1 1220 (aromatic 
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ether). 1 H NMR (d6-DMSO,DMSO) 5.18-5.21 ppm (d,4,Ar-CH2-0); 
6.99-7.14 (m,14,ArH). 
1,2-Dibenzyloxy-4-nitrobenzene 77a: 76a (14.5 g, 50 
mmol) was dissolved in glacial acetic acid (150 mL) and the 
solution was cooled to 10°C. To this solution was added 
dropwise nitric acid (6.7 mL, 100 mmol) dissolved in glacial 
acetic acid (40 mL). Addition of the nitric acid solution 
occurred over 1 h and the temperature of the solution was 
not allowed to exceed 15°C. After the addition was complete 
the solution was allowed to stir at room temperature for 
2.5 h. The reaction mixture was poured into water (400 mL) 
and the precipitate was collected by filtration to yield 
15.8 g (94%) of 77a as an pale yellow solid, 97-98°C [lit. 
(43) mp 98.5-9°C.). (IR(KBr)) cm-1 1225 (aromatic ether). 
1H NMR (d6-DMSO,DMSO) 5.16-5.19 ppm (d,4,Ar-CH2-0l; 7.02-
7.45 (m,13,ArH). 
3,4-Dibenzyloxyaniline.HCl 78a: 77a (10 g, 29.8 mmol) 
was placed in a mixture of water/ethanol (500 mL, 3:2). 
Sodium dithionite (42 g, 241 mmol) was added and the mixture 
was heated at reflux for 2 h. The solution was concentrated 
to a volume of 150 mL under reduced pressure. The solution 
was extracted with ethyl acetate (3 x 60 mL) and the organic 
layers were combined and dried with magnesium sulfate. The 
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organic layer was then saturated with HCl gas until 
precipitation occurred. The saturation continued for an 
additional 5 min. The mixture was cooled in the freezer for 
several hours. The precipitate was collected by filtration 
yielding 10.05 g (97%) of 78a as a white solid, mp 203-205°C 
[lit. (46) mp 197
°
C.]. IR(KBr) cm-1 2610 (amine salt). 1H 
NMR (d6-DMSO,DMSO) 5.15-5.18 (d,4,Ar-CH2-0); 6.83-7.25 
(m,13,ArH); 9.78 (s,3,NH3@). 
N-(3,4-Dibenzyloxyphenyl)urea 79a: 78a (10.0 g, 29.3 
mmol) and sodium cyanate (5.7 g, 87.6 mmol) were placed in 
acetonitrile (75 mL). The mixture was stoppered and allowed 
to stand at room temperature for 48 h. To the mixture was 
added dropwise over 30 min concentrated HCl (10 mL). The 
mixture was evaporated to dryness under reduced pressure. 
Water (100 mL) was added to the residue and the crude 
product was collected by filtration. Recrystallization in 
50% aqueous methanol yielded 8.0 g (78.3%) of 79a as a faint 
blue solid mp 160
°C. IR(KBr) cm-1 1625 (C=O, amide). 
1
H 
NMR (d6-DMSO,DMSO) 5.03-5.06 ppm (d,4,Ar-CH2-0l; 5.72 
(s,2,NH2); 6.87-7.39 (m,13,ArH); 8.31 (s,1,NH). 
Anal.: calculated for c21H20N2o3: C, 72.4; H, 5.79; 
N, 8.04. Found: C, 72.29; H, 5.85; N, 7.97. 
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N-(3,4-Dihydroxyphenyl)urea 80a: Debenzylation of 79a 
was performed analogous to the procedure for74a: 79a (8.39 
g, 24.1 mmol) and 10% palladium on carbon (1 g) were placed 
in methanol (100 mL). After the appropriate amount of 
hydrogen was consumed the catalyst was removed by gravity 
filtration. The filtrate was concentrated to an oil under 
reduced pressure. Water (30 mL) was added the oil and 
heated to .boiling. The hot solution was filtered through 
carbon and then cooled. The resulting precipitate was 
collected by filtration to yield 2.93 g (72.3%) of 80a as a 
white solid, mp 193°C (dec.). IR(KBr) cm-1 1620 (C=O, 
amide). 
1
H NMR (d6-DMSO,DMSO) 5.58 ppm (s,2,NH2); 6.53-6.95 
(m,3,ArH); 8.06 (s,1,NH); 8.29-8.77 (a,2,Ar0h). 
Anal.: calculated for c7H8N2o3: C, 50.00; H, 4.79; N, 
16.65. Found: C, 50.01; H, 4.81; N, 16.62. 
N-(3,4-Dibenzyloxyphenyl)benzamide 79b: 78a (7.0 g, 
20.5 mmol) and triethylamine (5.5 mL) were placed in ethyl 
acetate (70 mL). To the solution was added dropwise benzoyl 
chloride (4 mL, 34.2 mmol) dissolved in ethyl acetate (25 
mL). The reaction mixture was stirred at room temperature 
for 2 h. The solvents were removed under reduced pressure 
to leave a residue. Water (100 mL) was added to the residue 
and stirred for 30 min. The crude product was removed by 
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filtration and recrystallized from cold methanol. The 
product was collected by filtration to yield 5.0 g (59.6%) 
of 79b as a white solid, mp 155°C. IR(KBr) cm-1 1650 (C=O, 
amide). 1H NMR (d6-DMSO,DMSO) 5.11-5.14 ppm (d,4,Ar-CH2-0); 
6.76-8.01 (m,18,ArH); 9.67 (s,1,NH). 
Anal.: calculated for c27H23No3: C, 79.19; H, 5.66; 
N, 3.42. Found: C, 79.24; H, 5.94; N, 3.40. 
N-(3,4-Dihydroxyphenyl)benzamide 80b: Debenzylation 
under reducing conditions was performed analogous to the 
procedure of 74a: 79b (4.0 g, 9.8 mmol) was placed in 
methanol (100 mL) with 10% palladium on carbon (1 g) 
present. After the appropriate amount of hydrogen was 
consumed the catalyst was removed by gravity filtration. 
The solution was concentrated to an oil under reduced 
pressure. Water (60 mL) was added to the oil and the 
mixture was heated to boiling. The hot solution was 
filtered through carbon and the filtrate was cooled. The 
resulting precipitate was collected by filtration to yield 
1.2 g (53.4%) of 80b as white solid mp 187-8°C [Lit. (56) mp 
188.5°C.]. IR(KBr) cm-1 1660 (C=O, amide). 1H NMR (d6-
DMSO,DMSO) 6.62-7.96 ppm (m,8,ArH); 8.65-8.95 (d,2,Ar0H); 
9.90 (s,1,NH). 
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N-(3,4-Dihydroxyphenyl)methanesulfonamide SOc: 3,4-
Dibenzyloxyaniline.HCl, 78a, (2.0 g, 5.9 mmol) and 
triethylamine (8 mL) were placed in ethyl acetate (50 mL) at 
0°C. To this solution was added methanesulfonyl chloride 
(0.45 mL, 5.9 mmol) dissolved in ethyl acetate (50 mL). 
After the addition was complete the solution was maintained 
at 0°C for 1 h and then allowed to warm to room temperature. 
Solids were removed from the reaction mixture by filtration. 
The filtrate was concentrated to a residue under reduced 
pressure. Water (50 mL) was added to the residue and the pH 
of the solution was adjusted to 1. The crude product was 
collected by filtration. Debenzylation of the crude product 
was performed analogous to the procedure of 74a. After the 
appropriate amount of hydrogen had been consumed the 
catalyst was removed by gravity filtration. The solution 
was concentrated to an oil under reduced pressure. A small 
amount of toluene was added to the oil and removal of the 
solvent under reduced pressure was continued. Ethyl acetate 
(30 mL) was added to the oil and the mixture was stirred for 
30 min. Solids were removed by filtration. To the filtrate 
was added ligroine until turbidity of the solution was 
detected. The solution was filtered and ligroine was added 
to the filtrate again until turbidity was detected. After 
the third addition of ligroine the solution was filtered, 
and sufficient ligroine was added to the filtrate to 
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precipitate the pure product. The precipitate was collected 
by filtration yielding 720 mg (20.9%) of SOc as a gray 
solid, mp 144-5°C (dec.). 1H NMR (d6-DM50,TM5) 2.83 
(s,3,CH3); 6.51-6.67 (m,3,ArH); 8.76 (s,1,NH); 9.07 
(s,2,ArOH). 
Anal.: calculated for c7H9No45: C, 41.37; H, 4.46; N, 
6.89; 5, 15.77. Found: C, 41.48; H,4.50; N, 6.88; 5, 
15.72. 
N-(2-Methanesulfonyl-4,5-dibenzyloxyphenyl) 
methanesulfonamide 81: 3,4-Dibenzyloxyaniline.HCl, 78a, 
(10.0'g, 29.3 mmol) and triethylamine (10 mL) were placed in 
ethyl acetate (100 mL). To this was added dropwise 
methanesulfonyl chloride (3 mL, 38.9 mmol) dissolved in 
ethyl acetate (50 mL). The reaction was stirred at room 
temperature for 1 h. The solids were removed by filtration 
and placed in water (100 mL). The pH of the solution was 
made acidic and the crude product was removed by filtration. 
Recrystallization from methanol yielded 5.2 g (38.4%) of 81 
as a white solid mp 180-1°C. 1H NMR (d6-DM50,DM50) 3.47 ppm 
(s,6,CH3); 5.15-5.18 (d,4,Ar-CH2-0l; 7.08-7.41 (m,13,ArH and 
NH). 
Anal.: Calculated for c22H23N0652: C,57.25; H, 5.02; 
N, 3.03. Found: C, 57.18; H, 5.03; N, 2.98. 
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N-(2-methanesulfonyl-4,5-dihydroxyphenyl) 
methanesulfonamide 82: Debenzylation of 81 under reducing 
conditions was performed analogous to the procedure of 74a: 
� (4.9 g, 12.8 mmol) and 10% palladium on carbon (1 g) were 
placed in methanol (100 mL). After the appropriate amount 
of hydrogen was consumed the catalyst was removed by gravity 
filtration. The filtrate was concentrated to an oil under 
reduced pressure. Water (100 mL) was added to the oil and 
the pH of the solution was adjusted to 1.5. The crude 
product was collected by filtration and placed in boiling 
water (100 mL). The hot solution was filtered through 
carbon and the filtrate was cooled. The resulting 
precipitate was collected by filtration to yield �.15 g 
(82.7%) of 82 as a white solid, mp 219°C (dec.). 1H NMR 
(d6-DM50,DM50) 3.43 (s,6,CH3); 6.76 (s,3,ArH and NH) 9.25-
9 . 51 ( d , 2 , A rOH ) . 
Anal.: calculated for c8H11No652: C, 34.15; H, 3.94; 
N, 4.97; 5, 22.79. Found: C, 34.22; H, 3.98; N, 4.93; 5, 
22.75. 
3,4-Dibenzyloxybenzonitrile 76b: 3,4-
Dihydroxybenzonitrile, 75b, (10.0 g, 74 mmol), anhydrous 
potassium carbonate (25.75 g, 186.6 mmol) and benzyl 
chloride (20 mL, 174.6 mmol) were placed in n-butanol (70 
mL) and heated at reflux for 40 h under a nitrogen 
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atmosphere. The solution was concentrated to an oil under 
reduced pressure. Water (200 mL) was added to the oil and 
the solution was extracted with ethyl acetate (3 X 60 mL). 
The organic layers were combined, dried over magnesium 
sulfate and filtered. The filtrate was concentrated to an 
oil under reduced pressure. Methanol (30 mL) was added to 
the oil and the solution was cooled in the freezer two days. 
The resulting precipitate was collected by filtration to 
yield 17.5 g (75%) of 76b as a white solid, mp 58-9°C. 
IR(KBr) cm-1 2260 (nitrile). 1H NMR (d6DMSO,DMSO) 5.01-5.04 
ppm (d,4,Ar-CH2-0l; 6.89-7.43 (m,13,ArH). 
Anal.: calculated for c21H17No2: C, 79.97; H, 5.43; 
N, 4.44. Found: C, 79.87; H, 5.52; N, 4.33. 
2-Nitro-4,5-dibenzyloxybenzonitrile 77b: 76b (19.0 g, 
60.3 mmol) was placed in nitric acid (50 mL). To this was 
added dropwise sulfuric acid (10 mL). The tempe·rature was 
maintained at 25-30°C during the course of the reaction. 
The mixture was stirred for 3 h and then poured into water 
(300 mL). The crude product was collected by filtration and 
recrystallized from methanol twice. Collection of the 
product by filtration yielded 16.8 g (77.4%) of 77b as a 
yellow solid, mp 186-7°C. IR(KBr) cm-1 2275 (nitrile). 1H 
NMR (d6-DMSO,DMSO) 5.37 ppm (s,4,Ar-CH2-0l; 7.42 
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(s,10,benzyl ArH); 7.83 (s,1,benzonitrile ArH); 8.01 
(s,1,benzonitrile ArH). 
Anal.: calculated for c21H16N2o4: C, 69.99; H, 4.47; 
N, 7.77. Found: C, 69.61; H, 4.57; N, 7.42. 
2-Cyano-4,5-dibenzyloxyaniline.HCl 78b: 77b (2.9 g, 
8.1 mmol) and sodium dithionite (12.0 g, 68.9 mmol) were 
placed in 50% aqueous ethanol (300 mL). The mixture was 
heated at reflux for 2h. The solvent was reduced to 50 mL 
under reduced pressure. Water (100 mL) was added to the 
remaining volume and the aqueous solution was extracted with 
ethyl acetate (3 X 60 mL). The organic layers were 
combined, dried over magnesium sulfate and filtered. HCl 
gas was passed through the filtrate for 15 min. The 
solution was set in the freezer for 2 days. The resulting 
precipitate was collected by filtration yielding 2.1 g 
(70.6%) of 78b as a white solid, mp 180-3°C. lR(KBr) cm-1 
2665 (amine salt); 2250 (nitrile). 1H NMR (d6-DMSO,DMSO) 
4.99-5.12 ppm (d,4,Ar-CH2-0); 6.99-7.38 (m,15,ArH and 
NH3 �). 
Anal.: calculated for c21H18N2o2.HCL: C, 68.75; H, 
5.22; N, 7.63; Cl, 9.66. Found: C, 68.84; H, 5.23; N, 
7.59; Cl, 9.63. 
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N-(2-Cyano-4,5-dibenzyloxyphenyl)benzamide 83a: 78b 
(750 mg, 2 mmol) and triethylamine (2 mL) were placed in 
ethyl acetate (50 mL). To this was added dropwise benzoyl 
chloride (0.5 mL, 4.3 mmol) dissolved in ethyl acetate 
(10 mL). The reaction mixture was stirred at room 
temperature for 12 h. The crude product was collected by 
filtration and recrystallized from water to yield 820 mg 
(94.5%) of 83a as a white solid, mp 169-70°C. IR(KBr) cm-1 
2265 (nitrile); 1655 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 
5.19 ppm (s,4,Ar-CH2-0); 7.40-8.02 (m,17,ArH); 10.43 
(s,1,NH). 
Anal.: calculated for c28H22N203 X 1.25 H20: C, 
73.58; H, 5.40; N, 6.12. Found: C, 73.20; H, 5.22; N, 6.08. 
N-(2-Cyano-4,5-dihydroxyphenyl)benzamide 84a: 
Debenzylation of 83a was performed analogous to the 
procedure of 74a: 84a (750 mg, 1.7 mmol) and 10% palladium 
on carbon (250 mg) were placed in methanol (50 mL). After 
the appropriate amount of hydrogen had been consumed the 
catalyst was removed by gravity filtration. The filtrate 
was concentrated to an oil under reduced pressure. Water 
(20 mL) was added to the oil and the solution was cooled. 
The resulting precipitate was collected by filtration and 
recrystallized from water to yield 60 mg (13.7%) of 84a as 
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an orange solid, mp 258°C (dec.). IR(KBr) cm-1 2250 
(nitrile); 1665 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 7.29-
7.87 ppm (m,9,ArH and ArOH); 13.05 (s,1,NH). 
Anal.: calculated for c14H10N203 X 1.6 H20: c, 59.40; 
H, 4.70; N, 9.89. Found: C, 59.45; H, 4.60; N, 9.53. 
N-(2-Cyano-4,5-dibenzyloxyphenyl)acetamide 83b: 78b 
(1.0 g, 2.8 mmol) and sodium acetate (0.6 g, 7.3 mmol) were 
placed in acetic anhydride (20 mL). The solution was 
allowed to stir at room temperature for 24 h. The solution 
was poured into water (50 mL) and allowed to stir for an 
additional 24 h. The crude product �as collected by 
filtration and recrystallized from water to yield 870 mg 
(85.6%) of 83b as a white solid, mp 157-8°C. IR(KBr) cm-1 
2265 (nitrile); 1605 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 
2.05 ppm (s,3,CH3); 5.17 (s,4,Ar-CH2-0); 7.27-7.43 
(m,12,ArH); 9.96 (s,1,NH). 
Anal.: calculated for c23H20N2o3: C, 74.17; H, 5.41; 
N, 7.52. Found: C, 74.05; H, 5.49; N, 7.46. 
N-(2-Cyano-4,5-dihydroxyphenyl)acetamide 84b: 
Debenzylation of 83b was performed analogous to the 
procedure of 74a: 83b (800 mg, 2.2 mmol) and 10% palladium 
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on carbon (250 mg) were placed in methanol (50 mL). After 
the appropriate amount of hydrogen had been consumed the 
catalyst was removed by gravity filtration. The filtrate 
was concentrated to an oil under reduced pressure. Water 
(20 mL) was added to the oil and heated to boiling. The 
solution was filtered through carbon and cooled. The 
resulting precipitate was collected by filtration to yield 
210 mg (49.7%) of 84b as a light orange solid, mp 217°C 
(dec.). IR(KBr) cm-1 2270 (nitrile); 1605 (C=O, amide). 1H 
NMR (d6-DMSO,DMSO) 2.01 PPM (s,3,CH3); 7.33 (s,2,ArH); 8.31-
8.39 (d,2,Ar0H); 9.98 (s,1,NH). 
Anal.: calculated for c9H8N2o3: C, 56.25; H, 4.19; N, 
14.57. Found: C, 56.07; H, 4.37; N, 14.22. 
2-Nitro-4,5-dibenzyloxytoluene 77c: 4-Methylcatechol, 
75c, (10.0 g, 80.6 mmol), anhydrous potassium carbonate 
(22.25 g, 161.2 mmol) and benzyl chloride (22 mL, 192 mmol) 
were placed in n-butanol (70 mL). The mixture was heated at 
reflux for 20 h under a nitrogen atmosphere. The solution 
was concentrated to an oil under reduced pressure. Water 
(50 mL) was added to the oil and the aqueous mixture was 
extracted with ethyl acetate (3 X 30 mL). The organic 
layers were combined and dried with magnesium sulfate. The 
solution was concentrated to an oil under reduced pressure. 
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Glacial acetic acid (70 mL) was added to the oil and the 
solution cooled to 10°C. Nitric acid (7 mL, 161.1 mmol) was 
added dropwise to the solution. The mixture was stirred at 
10°C for 1 h and then allowed to stir at room temperature 
for 2 h. The mixture was then poured into water (500 mL) 
and the crude product collected by filtration. 
Recrystallization in cold methanol (100 mL) yielded 8.3 g 
(29%) of 77c as a white solid, mp 98-9°C [Lit. (55) mp 98-
100°C]. IR(KBr) cm-1 1240 (aromatic ether). 1 H NMR (d6-
DMSO,TMS) 2.51 ppm (s,3,CH3); 5.22-5.28 (d,4,Ar-CH2-0); 
7.21-7.75 (m,12,ArH). 
2-Methyl-4,5-dibenzyloxyaniline.HCl 78c: 78c was made 
according to the procedure of Burton et a1.57: 77c (14.5 g, 
41.5 mmol) was placed in dioxane (50 mL). To this was added 
raney nickel (4 g) suspended in dioxane (50 mL). The 
mixture was hydrogenated until the appropriate amount of 
hydrogen had been consumed. The catalyst was removed by 
gravity filtration. To the filtrate were added concentrated 
hydrochloric acid (20 mL) and ethyl acetate (100 mL). The 
precipitate was collected by filtration and washed with 
ethyl acetate to yield 9.25 g (62.8%) of 78c as a white 
solid, mp 209°C (dec.). IR(KBr) cm-12675 (amine salt). 1H 
NMR (d6-DMSO,DMSO) 2.24 ppm (s,3,CH3); 5.08-5.13 (d,4,Ar­
CH2-0); 7.05-7.40 (m,12,ArH); 10.00 (s,3,NH3 @). 
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Anal.: calculated for c21H21No2.HC1: C, 70.88; H, 
6.23; N, 3.93; Cl, 9.96. Found: C, 70.76; H, 6.28; N, 
3.91; Cl, 10.02. 
N-(2-Methyl-4,5-dibenzyloxyphenyl)benzamide 85: 78c 
(4.0 g, 11.3 mmol) and triethylamine (5 mL) were placed in 
ethyl acetate (100 mL). To this was added dropwise benzoyl 
chloride (1.5 mL, 12.8 mmol) dissolved in ethyl acetate (50 
mL). The mixture was heated at 40°C for 30 min. The 
solution was cooled to room temperature and filtered. The 
solids were placed in water (100 mL) and the pH of the 
solution adjusted to 1 with concentrated hydrochloric acid. 
The precipitate was collected by filtration yielding 1.84 g 
(38.5%) of 85 as a white solid, mp 138-40°C. IR(KBr) cm-1 
1650 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 2.19 ppm 
(s,3,CH3); 5.08-5.14 (d,4,Ar-CH2-0); 6.99-7.91 (m,17,ArH); 
9.74 (s,1,NH). 
Anal.: calculated for c28H25No3: C, 79.41; H, 5.95; 
N, 3.31. Found: C, 79.29; H, 5.95; N, 3.28. 
N-(2-Methyl-4,5-dihydroxyphenyl)benzamide 86: 
Debenzylation of 85 was performed analogous to the procedure 
of 74a. 85 (1.33 g, 3.2 mmol) and 10% palladium on carbon 
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(1 g) were placed in methanol (100 mL). After the 
appropriate amount of hydrogen had been consumed the 
catalyst was removed by gravity filtration. The filtrate 
was concentrated to an oil under reduced pressure. Water 
(50 mL) was added to the oil and heated to boiling. The hot 
solution was filtered through carbon and the filtrate 
cooled. The precipitate was collected by filtration 
yielding 500 mg (64.3%) of 86 as a light orange solid, mp 
8 0 -1 6 1 1 9-91 C. IR(KBr) em 1 50 (C=O, amide). H NMR (d6-
DMSO,DMSO) 2.03 ppm (s,3,CH3); 6.60 (s,1,catechol ArH); 6.76 
(s,1,catechol ArH); 7.43-7.98 (m,5,benzamide Ar!3_); 8.71-8.76 
(d,2,Ar0H); 9.56 (s,1,NH). 
Anal.: calculated for c14H13No3: C, 69.13; H, 5.39; N, 
5.76. Found: C, 69.22; H, 5.44; N, 5.73. 
3,4-Dihydroxyaniline.HCl 88: 4-Nitrocatechol, 87, 
(10.0 g, 64.5 mmol), 10% palladium on carbon (250 mg) and 
concentrated hydrochloric acid (10 mL) were placed in 
methanol (100 mL). After the appropriate amount of hydrogen 
was consumed the catalyst was removed by gravity filtration. 
The solvent was concentrated to 5 mL under reduced pressure. 
Ethyl acetate/isopropanol (50 mL, 3:2) was added to the 
residue. The precipitate was collected by filtration to 
yield 7.9 g (95%) of 88 as a gray solid, mp 243-5°C [Lit. 
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(58) mp 224-7°C.]. IR(KBr) cm-1 2670 (amine salt). 1H NMR 
(d6-DMSO,DMSO) 6.56-6.84 ppm (m,3,ArH); 9.20-10.00 (m,5,Ar0H 
and NH3 @). 
Anal.: calculated for c6H7No2.HC1: C, 44.60; H, 4.99; 
N, 8.66; Cl, 21.94. Found: C, 44.58; H, 5.00; N, 8.65; Cl, 
22.03. 
N-(3,4-Dihydroxyphenyl)acetamide 80d: 88 (4.9 g, 37.9 
mmol) was placed in water (100 mL). To the aqueous solution 
was added a mixture of acetic anhydride (5.0 mL, 37.9 mmol) 
and sodium acetate (3.1 g, 37.9 mmol) in acetic acid (5 mL). 
The mixture was heated at 60°C for 15 min. and then allowed 
to stand at room temperature for 12 h. The solution was 
filtered through carbon and the solvent of the filtrate was 
removed under reduced pressure. Ethyl acetate (100 mL) was 
added to the residue; heated to boiling and filtered hot. 
The remaining solid was treated twice more with ethyl 
acetate and the filtrates were combined. The volume of the 
solvent was reduced under reduced pressure until a 
precipitate occurred. The solution was cooled and the 
product was collected by filtration to yield 3.56 g (70%) of 
80d as a light gray solid, mp 186°C [Lit. (59) mp 173°C] 
IR(KBr) cm-1 1605 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 2.12 
ppm (s,3,CH3); 6.67-7.25 (m,3,ArH); 8.15-8.35 (d,2,Ar0H); 
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9.67 (s,1,NH). 
Anal.: calculated for c8H9No3: C, 57.48; H, 5.43; N, 
8.38. Found: C, 57.33; H, 5.43; N, 8.38. 
N-(2-Bromo-4,5-dihydroxyphenyl)benzamide 89a: N-(3,4-
Dihydroxyphenyl)benzamide, 80b, (500 mg, 2.1 mmol) was 
placed in glacial acetic acid (30 mL). To this was added 
bromine (0.1 mL, 2.0 mmol) dissolved in glacial acetic acid. 
The reaction mixture was stirred at room temperature for 2 
h. The solution was concentrated to an oil under reduced 
pressure. Isopropanol/chloroform (30 mL, 1:51 was added to 
the oil and the solution was cooled in the freezer for 24 h. 
The resulting precipitate was collected by filtration and 
recrystallized from chloroform to yield 450 mg (67%) of 89a 
as a wh�te solid, mp 208°C (dec.). IR(KBr) cm-
1 
1665 (C=O, 
amide). 1H NMR (d6-DMSO,DMSO) 6.95 ppm (s,1,catechol ArH); 
7.02 (s,1,catechol ArH); 7.48-8.03 (m,5,benzamide ArH); 9.40 
(s,2,ArOH); 9.74 (s,1,NH). 
Anal.: calculated for c13H10BrN03: C, 50.67; H, 
3.27;N, 4.54; Br, 25.93. Found: C, 50.44; H, 3.27; N, 
4.21; Br, 26.29. 
N-(2-Bromo-4,5-dihydroxyphenyl)methanesulfonamide 89b: 
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N-(3,4-Dihydroxyphenyl)methanesulfonamide, 80c, (500 mg, 2.5 
mmol) was placed in glacial acetic acid (25 mL). To this 
was added bromine (0.12 mL, 2.5 mmol) dissolved in glacial 
acetic acid (10 mL). The mixture was stirred at room 
temperature for 2 h. The solution was concentrated to an 
oil under reduced pressure. Chloroform (20 mL) was added to 
the oil and the solution was set in the freezer for 24 h. 
The precipitate was collected by filtration and 
recrystallized from chloroform to yield 300 mg (42.4%) of 
89b as a white solid, mp 155°C (dec.). 1H NMR (d6-
DMSO,DMSO) 2.92 ppm (s,3,CH3); 6.76 (s,1,ArH); 6.94 
(s,1,ArH); 8.99 (s,1,NH); 9.42-9.47 (d,2,ArOH). 
Anal.: calculated for c7H8BrNo4s: C, 29.80; H, 2.85; 
Br, 28.32. Found: C, 30.12; H, 2.90; Br, 27.99. 
N-(2-Bromo-4,5-dihydroxyphenyl)acetamide 89c: 80d (900 
mg, 5.4 mmol) was placed in glacial acetic acid (30 mL). 
Bromine (0.27 mL, 5.3 mmol) dissolved in glacial acetic acid 
(10 mL) was added dropwise .to the solution and the reaction 
mixture was stirred at room temperature for 2 h. The 
solution was concentrated to an oil under reduced pressure. 
Isopropanol/chloroform (60 mL, 1:5) was added to the oil and 
the mixture was set in the freezer for 24 h. The resulting 
precipitate was collected by filtration to yield 420 mg 
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(31.6%) of 89c as a white solid, mp 174°C (dec.). IR(KBr) 
cm-1 1610 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 1.99 ppm 
(s,3,CH3); 6.91 (s,2,ArH); 9.12 (s,3,Ar0H and NH). 
Anal.: calculated for c8H8BrN03: C, 39.05; H, 3.27; 
N, 5.69; Br, 32.47. Found: C, 38.88; H, 3.31; N, 5.65; Br, 
32.55. 
3,4-Dihydroxyphenylacetamide 91a: 3,4-
Dihydroxyphenylacetic acid, 90a, (5.0 g, 29.9 mmol) and 
thionyl chloride (3 mL, 41.0 mmol) were placed in ethyl 
acetate (100 mL). The mixture was heated at reflux for 6 h 
or until all HCl gas evolution had
,
ceased. The solution was 
concentrated to an oil under reduced pressure. Fresh ethyl 
acetate (100 mL) was added to the oil and this mixture was 
added dropwise into ammonium hydroxide (200 mL) over 30 min. 
The solution was heated to boiling and then cooled. The 
solution was concentrated to an oil under reduced pressure. 
Water (100 mL) was added to the residue and the pH of the 
solution was adjusted to 2. The solution was cooled, the 
resulting precipitate was collected by filtration and 
recrystallized from water to yield 4.2 (84%) of 91a as a 
white solid, mp 148-9°C [Lit. (60) mp 147°C.]. IR(KBr) cm-1 
1605 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 3.14 ppm 
(s,2,CH2); 6.41-6.74 (m,3,ArH); 6.80-7.28 (d,2,NH2); 8.66-
8.73 (d,2,ArOH). 
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3,4-Dihydroxycinnamamide 9lb: 3,4-Dihydroxycinnamic 
acid, 90b, (5.0 g, 27.9 mmol) and thionyl chloride (3.0 mL, 
41.0 mmol) were placed in ethyl acetate (100 mL) and heated 
at reflux for 6 h or until HCl gas evolution had ceased. 
The solution was concentrated to an oil under reduced 
pressure. Fresh ethyl acetate (100 mL) was added to the oil 
and the mixture added dropwise to ammonium hydroxide (200 
mL) over 30 min. The solution was heated to boiling and 
then cooled. The solution was concentrated to an oil under 
reduced pressure. Water (100 mL) was added to the oil and 
the pH of the solution was adjusted to 1. The solution was 
cooled and the resulting precipitate collected by filtration 
and recrystallized from water to yield 3.2 g (77.8%) of 91b 
as a white solid, mp 221-2°C [Lit. (61) mp 223°C.]. IR(KBr) 
cm-l 1660 (C=O, amide). 1H NMR (d6-DMSO,DMSO) 6.20-7.48 ppm 
(m,7,ArH and CH=CH and NH2); 9.04-9.42 (d,2,ArOH). 
3,4-Dihydroxyphenylacetamidoxime 93: 3,4-
Dihydroxyphenylacetonitrile, 92, (4.0 g, 26.8 mmol) and 
hydroxylamine sulfate (4.8 g, 29.3 mmol) were placed in 
water (80 mL). The pH of the solution was adjusted to 8 
with 50% sodium hydroxide. The solution was stirred under a 
nitrogen atmosphere at 45°C for 3 h. The solution was 
concentrated to an oil under reduced pressure. Absolute 
ethanol (100 mL) was added to the oil, cooled and filtered. 
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The filtrate was concentrated under reduced pressure leaving 
a residue. Water (25 mL) was added to the residue, the pH 
adjusted to 2, and the solution filtered through carbon. 
The filtrate was concentrated to an oil under reduced 
pressure. Absolute ethanol/ethyl acetate (25 mL, 1:11.5) 
was added to the oil and the mixture was cooled in the 
freezer for 24 h. The resulting crystals were collected by 
filtration to yield 1.52 g, (23.4%) of 93 as a white solid, 
mp 158-60°C [Lit. (62) mp 158 C0]. 1H NMR (d6-DMSO,DMSO) 
3.50 ppm (s,2,CH2l; 6.69-6.80 (m,3,ArH); 8.50-9.25 (m,4,Ar0H 
and NH2l; 10.94 (s,1,NH-OH); 12.83 (s,1,NH-OH). 
Anal.: calculated for c8H10N2o3.HC1: C, 43.95; H, 
5.07; N, 12.77; Cl, 16.21. Found: C, 43.82; H, 5.07; N, 
12.77; Cl, 16.28. 
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